

Taylor & Francis



Expert Review of Vaccines

ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: https://www.tandfonline.com/loi/ierv20

Update on vaccination of preterm infants: a systematic review about safety and efficacy/ effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology.

Elena Chiappini, Chiara Petrolini, Elena Sandini, Ameila Licari, Lorenza Pugni, Fabio A Mosca & Gianluigi Marseglia

To cite this article: Elena Chiappini, Chiara Petrolini, Elena Sandini, Ameila Licari, Lorenza Pugni, Fabio A Mosca & Gianluigi Marseglia (2019): Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology., Expert Review of Vaccines, DOI: <u>10.1080/14760584.2019.1604230</u>

To link to this article: <u>https://doi.org/10.1080/14760584.2019.1604230</u>



Accepted author version posted online: 05 Apr 2019.



🖉 Submit your article to this journal 🕑



View Crossmark data 🗹



Publisher: Taylor & Francis

Journal: Expert Review of Vaccines

DOI: 10.1080/14760584.2019.1604230

Review

Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology.

Elena Chiappini¹*, Chiara Petrolini², Elena Sandini², Ameila Licari³, Lorenza Pugni⁴, Fabio A Mosca^{4,5} and Gianluigi Marseglia³

¹Pediatric Infectious Disease Unit, Anna Meyer Children's University Hospital, Department of Health Science, University of Florence, Florence, Italy.

²Department of Health Sciences, University of Florence, Florence, Italy.

³Pediatric Clinic, IRCCS Policlinico "S. Matteo" Foundation, University of Pavia, Pavia, Italy.

⁴Neonatal intensive care unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

⁵University of Milan. Department of Clinical Sciences and Community Health, Milan, Italy.

*Corresponding author: Elena Chiappini, Pediatric Infectious Disease Unit, Anna Meyer Children's University Hospital, Florence, Viale Gaetano Pieraccini, 24,50139 Florence

Email: elena.chiappini@unifi.it

Abstract

Introduction: Preterm infants (PIs) are at increased risk of vaccine preventable diseases (VPDs). However delayed vaccination start and low vaccine coverage are still reported.

Areas covered: This systematic review includes 37 articles on preterm vaccination published in 2008-2018 in PubMed. Both live attenuated and inactivated vaccines are safe and well tolerated in PIs. Local reactions, apnea and reactivity changes are the most frequently reported adverse events. Lower gestational age and birth weight, preimmunization apnea, longer use of continuous positive airway pressure (CPAP) are risk factor for apnea. The proportion of PIs who develop protective humoral and cellular immunity is generally similar to full terms although later gestational age is associated to increased antibody IgG concentrations (i.e. against certain pneumococcal serotypes, influenza, hepatitis B virus and poliovirus 1) and increased mononuclear cells proliferation (i.e. after inactivated poliovirus). However vaccinated PIs have lower hospitalizations, ambulatory visits and notifications of VPDs.

Expert opinion: PIs can be safely and adequately protected by available vaccines with the same schedule used for full terms. However data at this regard have been almost exclusively retrieved by studies using a 3-dose primary series for pneumococcal and hexavalent vaccines, while further studies are needed regarding the 2+1 schedule. Apnea represents a nonspecific stress response in PIs, thus those hospitalized at 2 months should have cardio-respiratory monitoring for 2 days after their first vaccination.

Keywords: preterm infant, vaccinations, safety, immunogenicity, efficacy, effectiveness.

Article highlights

- Despite recommendation to vaccinate preterm infants at the same scheduled age as full-term children, a delay is commonly experienced in these population.
- Preterm children may experience vaccine preventable diseases, which tend to be more severe, due to an impaired immune response
- Based on our research the overall safety and tolerability of the scheduled vaccines showed no differences in preterm and full-term infants, and live attenuated vaccines as well are considered safe.
- Postponing vaccination is justified only in clinically unstable infants
- Preterm infants already hospitalized at the time of first vaccination should receive their first dose in the neonatal ward, particularly those infants born≤31 weeks of gestation, those with a birth weight 2 ≤kg, those suffering from apnoea/bradycardia and those with severe bronchopulmonary dysplasia. There should then be monitoring of the clinical conditions and the cardio-respiratory system as inpatients for two days.

1- Introduction

Among the nearly 13 million preterm births occurring each year worldwide, approximately 500,000 occur in Europe where the preterm birth rate varies between 5% and 9% [1,2]. In Italy, the proportion of preterm (<37 weeks gestation) and very preterm (<32 weeks gestation) births are about 7% and 1%, respectively, corresponding approximately to 38,000 and 5500 live births annually [3]. -Preterm infants (PIs) may develop several long term adverse consequences, such as cerebral palsy, sensory deficits, respiratory illnesses, cognitive and behavioral disabilities [4–6], and are at increased risk of infections due to defects in external barriers, lower levels of passively transferred maternal antibody, innate and adaptive immunity impairment, with the latter resulting in suboptimal B and T cell function [7-9]. Therefore, preterm infants may experience vaccine preventable diseases (VPD) with increased frequency and severity in the first months of life [10–12], such as pertussis [13], pneumococcal infections [14], and influenza [15]. According to the international recommendations preterm infants, who are otherwise healthy, should follow the same vaccination schedule used for full-term infants, based on their chronological age rather than corrected gestational age and regardless of their birth weight. Moreover, vaccine dosages normally given to full term infants should not be reduced or divided when given to PIs [16-21].

However, low vaccination coverage and schedules' delayed start have been reported in PIs [22-29]. Delayed beginning of vaccines' schedules seems to be associated with low birthweight, lower gestational age, hospitalization after discharge from the neonatal intensive care units (NICUs), paternal/maternal unemployment, increasing numbers of siblings in the family, lower socioeconomic status and ethnicities other than white [22, 30]. Fear of a weaker response to vaccines or of adverse events in preterm infants could be other reasons for the delay [31–34]; however several studies show that PIs are generally able to mount a protective adaptive immune response to most vaccines used in infant vaccination programmes [31, 35-36]. Moreover even if some adverse events like apnea and/or bradycardia have been reported to occur between 0 and 47% following vaccination in PIs, they are self-limiting non specific stress responses that commonly complicate other medical procedures without any long term sequelae [33-39]. The aim of the present study is to systematically review the available literature about vaccinations in PIs focusing on safety and immunogenicity/effectiveness.

2- Methods

A literature search was performed covering papers published from January 1st 2008 to 31st October 2018. The PubMed MEDLINE and Cochrane Library databases were systematically searched using the following terms combined using Boolean operators ("infant, preterm"[MeSH Terms]) AND "vaccination"[MeSH terms]). Only papers published in English were included. Reference lists of the retrieved articles were reviewed to identify other possible pertinent publications. Titles and abstracts of studies identified during the primary search were screened for inclusion, and papers containing prospective or retrospective

observational studies and clinical trials focusing on vaccination in PIs were included in this review. We included also studies assessing a comparison between full-term and PIs. Articles not pertinent to vaccines in PIs, commentaries, letters, case series (including less than 10 infants), case reports, reviews, duplicates and papers not written in English were excluded. Data were independently extracted by two different authors (CP and ES) and any disagreements or conflicts were discussed with a third author (EC). The following data were extracted for each study: year of publication, study type and location, gestational age (GA) of the study population, number of children included, type of vaccination administered, study outcomes (i.e.: laboratory indicators of immunogenicity; clinical indicators of efficacy or effectiveness; reported adverse events for vaccines' safety), follow up and possible biases and limitations of the study. The PRISMA Statement has been used for reporting of the systematic review filling a 27-item checklist (Table 1) and a four-phase flow diagram (Figure 1) [40].

3-Results

Initially, 61 studies were identified through the search strategy (Table 2) and additionally another 15 studies were retrieved after evaluation of the studies' references; 39 articles were excluded relying on studies' abstracts or titles because they didn't satisfy eligibility criteria (Figure 1).

Finally, 37 relevant articles were included in this systematic review: 24 articles had as the main objective vaccines' safety in preterm infants [34-35, 41-62]; while 18 and 4 articles investigated immunogenicity [31, 41-42, 46-50, 53-54, 63-67, 70,72,73] and effectiveness [45, 68-69, 71] as the main objective respectively. *3.1-Studies on vaccine safety.*

Safety was the main objective of 24 studies, overall including 789,165 preterm infants (Table 3) [34, 35, 41-62].

3.1.1-Studies on live attenuated vaccines'safety.

Live attenuated vaccines were investigated in 6 studies [41-46]. Measles vaccination's safety was evaluated by *Ichikawa et al.* in a prospective study including 17 PIs <34 weeks of gestation who received an early vaccination at 6 months of age in order to prevent the disease. No adverse reaction was reported, but the number of vaccinated infants in the present study was limited [41].

Saroha et al. in a prospective randomized trial found that Bacille Calmette-Guérin (BCG) vaccine may be safely given at birth to moderately PIs (31–33 weeks). The only complication observed in 3.4% of the 117 patients enrolled in the study was left axillary lymphadenopathy [42]. Another two studies aimed to determine the safety of BCG vaccination [43-44]. *Kjærgaard et al.* performed two randomized multicenter clinical trials in Denmark, overall involving 4262 children, of which 144 were aged 32 to 37 weeks of gestation. No difference was observed on either susceptibility of infections, growth, body composition or psychomotor development between patients that received or did not receive BCG vaccination at birth [43-44].

Two studies investigated safety of rotavirus vaccination in PIs [45-46]. A large population-based study by *Rouè et al.* showed no significant difference in severe adverse events incidence following rotavirus vaccination between preterm and full-term infants. [45]. *Omenaca et al.* in their phase IIIb randomized double blinded placebo-controlled trial including 165 PIs vaccinated with live-attenuated rotavirus observed a similar frequency of severe adverse events (SAEs) in the vaccinated and placebo groups (P = 0.266) [46]. The proportion of all and grade 3 solicited general adverse events (AEs) reported during the 15-day postvaccination follow-up period were similar in both the vaccinated and placebo groups, with irritability as the most common AE [46]. The most commonly reported unsolicited AEs were fever, irritability, gastrointestinal disorders and upper respiratory tract infections.

3.1.2-Studies on inactivated or subunit vaccines' safety.

Inactivated or subunit vaccines were investigated in 18 studies [34-35,47-62] (Table 3). *Tsuda et al.* in a prospective cohort study reported local redness as the only AE after *Haemophilus influenzae* (Hib) vaccination in 54 PIs [47]. Influenza A/H1N1 MF59-adjuvanted vaccination were studied by *Esposito et al.* in an open randomized trial including 101 infants. No difference in safety and tolerability were found between term and PIs. The only systemic adverse event consistently observed in all groups was fever, which was significantly more frequent after the first dose than after the second in all the groups [48].

An open-label prospective multicenter randomized controlled trial by *Kent et al.* evaluated the safety of the conjugate vaccine containing thirteen pneumococcal serotypes (PCV13) on PIs aged <35 weeks of gestation with different timing of administration: reduced schedule of PCV13 (at 2 and 4 months of age), accelerated schedule (at 2, 3 and 4 months of age) and extended schedule (at 2, 4 and 6 months of age) [49]. There was no significant difference in the frequency or severity of local and systemic AEs between vaccination schedules at any time point and no serious AEs were considered vaccine related [49]. Several studies found a similar or sometimes lower frequency of AEs related to multivalent vaccines in PIs compared to full term infants, probably as the result of a reduced immune response and ability to mount an inflammatory process [50-54].

Klein et al. described adverse events related to diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B (HBV), inactivated polio (IPV), pneumococcal vaccine (PCV) during the 30 days after each of 3 doses, comparing the frequency of AEs in preterm and full-term infants in 83 patients: no increase of medical attended events (MAEs) was found in the two groups comparing to the control period (postvaccination days 31–60)[50]. Moreover, in one retrospective study by McCrossan et al. none of the 344 PIs displayed an AE [51]. In a large observational self-controlled case series by Wilson et al. children acted as their own control counting the rate of events per day in an "at risk" period (i.e. immediate 3 days post vaccination at 2 months of age with DTaP-HBV-IPV-PCV) compared with the rate of events in a control period during which it would be unlikely that the exposure produced the outcome (9–18 days post-vaccination)[52]. Overall 771,453 children, of which 49,220 children <37 weeks of GA and 7,392 children \leq 32 weeks of GA, were enrolled in the study, showing a progressive reduction in admission to emergency room department or to hospital 3 days after vaccination at 2 months of age with increasing category of prematurity [52]. Omeñaca et al. enrolled 313 term and PIs in an open controlled prospective multicenter study. Local symptoms in the 4 days following the combined Haemophilus influenzae type B-Neisseria meningitidis serogroup C vaccine (Hib-MenC-TT) were lower compared with DTaP-HBV-IPV-PCV vaccine [53]. Large injection-site swellings after the booster dose were reported less frequently in the preterm group than in full-term group, occurring mainly at the DTaP-IPV injection site. No difference in grade 3 AEs were found between groups [53]. Similarly, in another study, assessing the safety of the 10-valent pneumococcal non typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 149 term and 137 Pls, the incidence of solicited general symptoms (i.e: fever, irritability, drowsiness, loss of appetite) was generally similar across the groups [54]. Considering local symptoms, such as redness or swelling, their incidence was lower in PIs than in the term group [54]. None of the reported serious AEs was considered causally related to vaccination. The most frequently reported unsolicited AEs in all groups were upper respiratory tract infections, together with injection site nodules after primary and booster vaccination in the term group. One episode of apnea was reported in a PI after the first primary dose, but it was not considered to be associated to the vaccination and resolved without sequelae [54].

Wilinska et al. studied 138 children born before 37 weeks of gestation (73 born ≤28 weeks GA and 65 born >28 weeks GA), who underwent vaccination as inpatient and monitored their cardiac and respiratory functions as well as body temperature over 72 hours after DTaP-IPV-PCV-Hib vaccination. Apnea and changes in reactivity (i.e. change in infants' behavior valued by Multidimensional Neonatal Infant Pain Scale-NIPS) were the relatively most frequent reported AEs. Infants who experienced apneas had significantly more frequently late onset sepsis and a history of longer use of continuous positive airway pressure (CPAP)[55].

Several studies found an increased incidence of apnea in PIs following vaccination with DTaP-IPV-PCV-Hib vaccine [34-35, 56-60]. Incidence of these reactions even if different in the reported studies declined with age, supporting the hypothesis that these cardiorespiratory events essentially represent nonspecific stress responses of very low birth weight (VLBW) PIs, whose maturity progresses with chronological age [34-35, 56-60]. In the study by *Anderson et al.* the incidence of apnea after the first DTaP-IPV- PCV-Hib vaccination was 8.4% in extremely PIs, while there was no reaction following the second dose at 4 months. Infants with apnea following the 2-month vaccine displayed significantly lower GA and birth weight. Unfortunately, only 50% cases with apnea after the first vaccination dose at 2 months were evaluated through a cardiorespiratory monitoring after the second dose at 4 months [56]. Similarly, in a prospective study by *Furck et al.* the risk of apnea decreased with increasing GA [57]. In this study the frequency of apnea/bradycardia after the first dose of DTaP-IPV-PCV-Hib vaccine in 473 preterm infants with a weight

<1500 g was 10.8% [57]. In a retrospective observational study by *Flatz-Jequier et al.* including 64 very low birth weight PIs aged <32 weeks, 33 infants developed a cardiorespiratory event after the first dose of DTaP-IPV-Hib vaccination and 6 of them required medical interventions after the second vaccine for a similar event, identifying a positive history of previous analogous AE as a significant risk factor for the recurrence of a cardiorespiratory event [35]. In the study by *Clifford et al.* evaluating the frequency of apnea and bradycardia up to 48 hours after DTPa-IPV-HBV-Hib-PCV7 and oral rotavirus vaccine at 2 and 4 months of age, 7 out of 38 preterm infants developed recurrent apnea after vaccination. Lower birth weight and ongoing hospitalization for complications related to prematurity increased the risk of a recurrent apnea following vaccination [34]. Accordingly, a large multicenter retrospective cohort study by *De Meo et al.* including 13926 extremely PIs showed an increase in the respiratory support need in the 3 days following vaccination compared with the 3 days preceding the procedure, particularly in infants of 23-34 weeks of GA compared with older PIs [58].

Other studies investigated possible risk factors for post-vaccination apnea other than lower GA, lower birth weight, lower chronological age and positive history of previous similar events [59-60].

A retrospective cohort study by *Hacking et al.* including 411 extremely PIs observed a higher incidence of apnea in PIs who had previously experienced septicemia and had a greater mean total accumulated time on CPAP prior to vaccination [59]. A multivariate analysis by *Klein et al.* identified age \leq 31 weeks of gestation, increased initial illness severity scores at birth, birth weight <2 kg and the presence of pre-vaccination apnea as independent risk factors for post-vaccination apnea [60].

Conversely, the only available randomized blinded controlled multicenter study investigating the incidence of apnea in PIs found no increased incidence of post-vaccination apnea[61]. They investigated the frequency of cardiorespiratory events after DTaP vaccination at 2 months of age in 191 PIs with a GA<37 weeks. Infants were randomly assigned to a group that received DTaP vaccine or a control group that did not. No significant differences in apnoea or bradycardia frequency were found between the two groups [61].

A randomized double blinded placebo controlled trial by *Ben Jmaa et al.* included 56 Pls <32 weeks of gestation vaccinated at 2 months of age randomized in two group: the ibuprofen treatment group and the placebo group. Ibuprofen treatment significantly attenuated the variation of cardio-respiratory event following first vaccine. Authors speculated that the inflammatory processes triggered by vaccine might be responsible for the respiratory depression often observed in Pls and suggested a possible protective role of ibuprofen [62].

3.2-Studies on vaccine immunogenicity and efficacy/effectiveness.

Immunogenicity and efficacy/effectiveness was assessed in 22 studies overall including 1,566,350 infants (Table 4-5) [31, 41-42, 45- 50, 53-54, 63-72].

3.2.1-Studies on live attenuated vaccines' immunogenicity and efficacy/effectiveness.

Live attenuated vaccines were investigated in 6 studies [41, 42, 45, 46, 63, 64]. The immunogenicity of the early *vs.* delayed BCG vaccination (BCG at birth vs BCG at 34 weeks gestational age) in moderately preterm infants was studied by in-vivo (i.e. Mantoux test and scar formation 6 months after BCG vaccination) and in-vitro methods (i.e. rise IFN-x after BCG vaccination) by *Saroha et al.* The overall immunogenicity of BCG in this study was 98.3% independently from the time of vaccine administration. [42]. Even *Faridi et al.* in a prospective observational study evaluated the immunogenicity of BCG administered to infants of 31–41 weeks gestation within 7 days after birth. The 95.8% of enrolled patients had either a reactive Mantoux test or positive leukocyte migration inhibition test 6 months after BCG vaccination [63].

Ichikawa et al. investigated immunogenicity of anti-measles vaccine at 6 months of age in PIs<34 weeks of gestation. Early vaccination at 6 months reached protective antibody titers in all cases 1 month after vaccination without a decay during the 12 months after vaccine [41].

A prospective study by *Ferreira et al.* compared the immune response to measles and varicella vaccination in infants born prematurely with those born full-term. The proportion of infants with protective humoral titers to measles and varicella after vaccination were similar in both groups [64].

Two studies focused on rotavirus vaccine immunogenicity and effectiveness [46, 45]. *Omenaca et al.* assessed immunogenicity of rotavirus vaccine dosing IgA specific antibody 30–83 days post-dose 2 in a randomized double blind multicenter controlled trial. Seroconversion rate was 85.7% in the vaccine group and 16.0% in the placebo group [46]. Effectiveness of rotavirus vaccination was the topic of the study performed by *Roué et al.* with the aim to evaluate the impact of the pentavalent rotavirus vaccine on the number of hospitalizations for rotavirus diarrhoea in preterm infants. A significant decrease in the number of hospitalizations for rotavirus infection in infants younger than 3 years of age in the three epidemic seasons following the vaccine introduction was found [45].

3.2.2-Studies on inactivated or subunit vaccines' immunogenicity and efficacy/effectiveness. Tsuda et al. evaluated the immunogenicity of Hib vaccine in PIs evaluating antibody antipolyribosylribitolphosphate (PRP) geometric mean concentrations (GMCs) after the third dose of vaccine. The seroconversion rate was lower, but not significantly, in preterm than in full term infants (85.2% vs. 92.4%) [47].

Immunogenicity of pneumococcal vaccine was investigated in 6 studies [31, 49, 54, 65, 66, 67], while the assessment of the PCV effectiveness was the aim of one study [68]. Regarding immunogenicity results are discordant. Two studies [54,65] reported protected specific antibody levels in high proportion of PIs, however several other authors found lower titers, especially against some serotypes such as 6B and 23F [31,49].

A trial by Omenaca et al. assessed immunogenicity of the PHiD-CV in two groups of preterm infants (those born between 27 and 30 weeks vs. those born between 31-36 weeks). At least 93% and 97.6% of infants in each group reached protective antibody titers 1 month after primary vaccination and after the booster dose respectively, without any difference in antibody titers between groups [54]. Szynczewska et al. assessed the concentration of specific IgG against serotypes of PCV7 in 60 PIs [65]. Ninety-one % and 100% of patients reached protective antibody concentrations after administration of three doses of the vaccine and after the booster dose respectively. Serotypes 6B and 23F were the least immunogenic ones[65]. On the other hand, only 36% term infants and 34% PIs achieved protective levels against all PVC7 vaccine serotypes following the primary vaccination [31]. Preterm birth adversely affected the GMCs to serotypes 4, 6B, 14, 19F, and 23F [31]. Immunogenicity of PCV13 was investigated in one RCT by Kent et al. including 199 PIs <35 weeks of GA, randomized to receive a reduced, accelerated and extended schedule of PCV13 [49]. Lack of seroprotection toward more than one-half of the PCV13 serotypes was seen in 25%, 12%, and 3% of participants receiving the reduced, accelerated and extended schedules respectively. Waning of pneumococcal antibody concentrations was evident at 12 months of age. Later gestational age was associated with an increase in post-primary vaccination IgG concentrations for some serotypes, while receipt of antenatal steroids was associated with decreased odds of seroprotection after primary vaccination for some serotypes [49].

An open-label, multicenter trial by *Martinón-Torres et al.* evaluated antipneumococcal antibody responses elicited by PCV13 with a longer follow up, evaluating specific IgG antibody 1 and 2 years after the fourth dose (toddler dose) in PIs compared with term infants. IgG GMCs in both infant groups at the 1-year and 2-year follow-up visits were lower than GMCs 1 month after the toddler dose for all serotypes. Particularly IgG GMCs in PIs were statistically significantly lower at both follow-up time points for serotypes 6B, 18C, 19A, 19F and 23F, while IgG GMCs for serotypes 5, 6A and 9V were statistically significantly lower in PIs at the 1-year follow-up only [67].

Despite controversial immunogenicity results the only study investigating antipneumococcal effectiveness found reassuring results. Authors assessed the impact of PCV7 on invasive pneumococcal disease (IPD) in PIs comparing those born in 2000 (prior to the recommendation to vaccinate with PCV7 preterm infants) with those born in 2007. A reduction in notifications of IPD in 2007 was found both in full term and in PIs, although this reduction was not significant in the latter. No PIs with reported IPD received full vaccination with booster dose according to the recommended schedule. In two IPD cases were both not vaccinated and presented with a serotype included in PCV7 [68].

Two studies focused on influenza vaccine [48,69]. *Esposito et al.* evaluated the immunogenicity of influenza A/H1N1 MF59-adjuvanted vaccine measuring antibody immediately before administration of dose 1 and 2 and 4 weeks after the dose 2. GMCs were significantly higher after the second dose and significantly lower in PIs <32 weeks of gestation, thus confirming that a very low GA may lead to a reduced immune response.

However seroprotection rates were >90% after the first dose in all the groups, suggesting that a single dose of vaccine administered after the sixth month of life can protect almost all children aged <23 months [48]. Shen et al. examined influenza-related healthcare use outcomes among preterm and full-term children aged 6–23 months. The effectiveness of seasonal influenza vaccination was evaluated by examining influenza-coded ambulatory visits (physician office and ED visits) during influenza season periods over five years in more than 600,000 patients. Full vaccination was associated with an overall 19% reduction in ambulatory visits, however a significant reduction was observed only in full term infants [69]. Klein et al. investigated the immunogenicity of the primary series of IPV given as part of a combined vaccine evaluating poliovirus type 3-specific memory T cell, poliovirus type 3-specific cell-mediated immunity and neutralizing antibody response against poliovirus serotypes 1, 2 and 3. Preterm and term infants developed comparable mean frequencies of poliovirus-specific memory T cell responses. Considering mononuclear cells proliferation (PBMCs), PIs were significantly less likely to have a positive stimulation index (SI) than term infants, while all infants had a seroprotective antibody response to all 3 poliovirus serotypes. However the GMCs to poliovirus serotype 1 was significantly lower in both the group of all preterm infants [50]. Two studies investigated immunogenicity or effectiveness of pertussis vaccination in PIs [70-71]. Vermeulen et al. assessed the persistence of the specific immune responses against Bordetella pertussis in three groups of one-year old children born prematurely: one group received a whole cell vaccine (Pw) for the primary vaccination and a two components acellular vaccine (Pa) as booster dose; the second group received a two component Pa vaccine for every dose of the schedule, the third group received a three component Pa vaccine. The antigen specific cellular immune response persisted at year of age, however acellular vaccines induced a lower specific Th1 type immune response compared with Pw vaccine [70]. Hviid in a large retrospective nationwide Danish study observed a reduced immunogenicity of whole cell pertussis vaccine in PIs after the first dose but the completed primary series was equally effective in preterm and full-term children [71].

Omenaca et al. found an optimal immunogenicity of Hib-MenC-TT vaccine in 309 PIs [53]. In the same study anti-HBV IgG levels were also measured as secondary objectives after concomitant coadministration of DTaP-HBV-IPV showing a gestational age-related profile, with the lowest levels observed in infants aged ≤31 weeks. Similar findings were evident in another study suggesting that PIs have lower humoral response to HBV than full-term infants in terms of GMCs but not in term of seroprotection rates[73].

4-Conclusion

Our findings are in general reassuring regarding the safety and immunogenicity of vaccines in PIs. Studies on BCG, rotavirus and measles vaccination found no increased risk of AEs. Considering inactivated/subunit vaccines, pain, redness and swelling in the injection site are frequently reported, as expected. However, large injection-site swellings after the booster dose have been reported less frequently in the preterm than in full-term infants by some authors [53, 54, 74], but not by others [75-77]. Some authors postulated that a reduced immune response in PIs could result in fewer AEs immediately following vaccination [52]. Apnea and changes in activity (i.e. drowsiness, irritability and loss of appetite) were other frequently reported adverse events [53-55]. Incidence of cardiorespiratory events vary widely (from 1% to 59.1% of PIs) [34-35, 56-62]. Most cardiorespiratory events resolved spontaneously or required minimal intervention [35]. A causal relationship between vaccination and the occurrence of cardiorespiratory events continues to be widely debated. This may be due to the lack of a control group in many studies, their retrospective nature, sample sizes too small to demonstrate statistically significant differences, the difficulty in distinguishing apnea due to vaccination from background instability and the frequent presence of confounding factors (i.e.: periventricular hemorrhage, bronchopulmonary dysplasia, history of sepsis during hospitalization). Moreover, the incidence of post vaccination apnea could be influenced by the so-called "healthy vaccinated" effect, by which clinicians wait until infants are more stable to immunize, thus reducing the observed incidence of adverse events. However, the chance of experiencing an apnea after vaccination seems to be related with lower GA and birth weight [56, 60], supporting the hypothesis that these cardiorespiratory events essentially represent nonspecific stress responses of preterm infants [35,58]. Moreover, newborns who experienced apnea after vaccination were those with a previous severe clinical condition such as late onset sepsis or requiring long time CPAP support [55, 59]. One important risk factor

for recurrence of cardiorespiratory event seems to be a positive history of previous similar adverse reaction, particularly in the 24 h prior to vaccine [35, 50, 60, 78].

Notably, the only controlled prospective randomized study by *Carbone et al.* [61] suggested that vaccination does not directly contribute to cardiorespiratory events showing no difference in occurrence or severity of apnea/bradycardia in vaccine recipients vs. controls. In this study clinical reviewers were blinded to vaccination status and study phase (before or after vaccination), but one possible bias of the study could be that PIs with unstable vital signs were excluded as were infants who required assisted ventilation. In conclusion given the risks of cardio-respiratory events but also the increased risk of VPDs, PIs who are still hospitalized at 2 months of age should be vaccinated prior to discharge from hospital and should be monitored for 48–72 h after vaccination. This is particularly important in PIs with VLBW with a previous history of cardiorespiratory events, especially in the 24 h prior to vaccination. When a cardiorespiratory AE to the first dose is suspected, consideration should be given to administering the second vaccination under controlled circumstances.

Considering immunogenicity, the proportion of PIs who developed humoral immunity were generally similar in preterm compared with full term infants for many vaccines, with contrasting results for PCV vaccines, even if PCV7 effectiveness was found to be high in preterm infants in one study [64, 66, 73]. Good seroprotection rate for Hib, MenC, HBV, influenza and IPV vaccinations were reported in PIs [47, 48, 50, 53, 72], even if lower gestational ages were associated to lower GMCs

in most of the studies and for most valences (i.e. HBV, Hib, IPV, influenza, pneumococcal and pertussis vaccine), suggesting a lower immunogenicity for PIs [31, 48, 50, 53, 67, 73].

Even if a possible impairment of Th1 response in PIs has been suggested [79-80], several results of studies documented an appropriate cellular immune response toward several vaccines (BCG, pertussis, IPV) [42, 50, 63, 70]. One study reported imbalance in Th1/Th2 response in recipients of acellular pertussis vaccination, depending on the vaccine type, but clinical impact of such a finding is unclear [70]. Unfortunately, only 4 studies evaluating vaccine effectiveness (rotavirus, influenza, PCV, and pertussis) were retrieved [45,68,69,71]. Notably, all the large population based studies documented no differences in vaccine effectiveness between preterm and full term infants.

Our review presents several limitations: our literature search might have missed some studies. However, two authors independently performed literature searches in order to minimize this possibility. The study design of the retrieved papers varied and some of them included small datasets, especially for live attenuated vaccinations, thus further investigations are required. In addition, data about extreme PIs are poor and a distinction of results according to grade of prematurity is not always performed in the studies enrolled.

5-Expert opinion

Neither gestational age nor birth weight should delay the decision to start vaccination in clinically stable PIs. Postponing vaccination is justified only in clinically unstable infants. If PIs are still hospitalized at the time at which they should be vaccinated they should receive their first vaccine in the neonatal ward monitoring them for 48–72 h after vaccination. This is particularly important for infants born ≤31 weeks of GA, with birth weight <2 Kg, with pre-vaccination apnea episodes or with severe bronchopulmonary dysplasia. Educational programs for health professionals and caregivers should be improved in order to avoid delay in vaccination of these infants.

Most of the available studies comparing the immunogenicity of DTaP-IPV-Hib-HBV and PCV in preterm and full term infants apply a 3-dose primary series of vaccination [31, 45, 50, 53-54, 65, 67-71, 73] as recommended by the Centers for Disease Control and Prevention [81]. Even if many countries like United Kingdom, Australia and Canada adopt a 3-dose primary series, other European countries, including Italy, apply a 2+1-dose primary series for hexavalent/pentavalent and pneumococcal vaccination. Currently only one study compared different schedules of immunization with PCV13 [49], showing lower specific IgG GMCs with the reduced schedule after the primary course but superior antibody concentrations after the booster dose in comparison with extended or accelerated schedules. According to some experts' opinions, it could be preferable to vaccinate very PIs with a 3-dose primary series of DTaP-IPV-HBV-Hib and PCV. However, further studies are needed in order to better understand the immunogenicity of the 2+1 schedule in very PIs (< 32 weeks of gestational age).

Specific issues should be considered regarding rotavirus vaccination considering the risk of transmission of the live attenuated virus in the stool of immunized PIs still hospitalized in NICUs. Several international guidelines recommend that rotavirus vaccine should be administered within 6 to 14 weeks and 6 days of age in order to minimize the potential risk of intussusception [82,83,84]. Canadian and American guidelines suggest rotavirus vaccine administration at or following discharge from the NICUs to prevent the spread of vaccine virus in the hospital setting with the risk of missing possible cardiorespiratory events but also the risk of missing the benefit of rotavirus vaccination in term of immunogenicity overcoming the specific time of administration of vaccine [82-83]. A possible compromise could be policy adopted by British guidelines recommending to vaccine PIs still hospitalized applying routine standard infection control precautions [84]. Further studies are needed to develop evidence-based recommendations regarding the necessity to monitor PIs with suspected cardio-respiratory event following the first vaccine when the second immunisation is performed, considering also direct and indirect costs of a prolonged hospitalization.

Although several studies have been retrieved, limited data are available regarding vaccine effectiveness in preterm infants, particularly after the schedule 2+1 for the hexavalent vaccine and PCVs. Therefore, further studies are needed in this respect, especially focusing on the more recently marketed vaccines (i.e. PCV13 and anti-meningococcal vaccines) and on the need for eventual additional booster doses. Moreover, future studies should analyse the potential differences between subgroups of preterm infants, such as extremely preterm ones (<29 weeks gestational age) to assess whether they need additional vaccine or earlier booster doses.

Funding

This paper was not funded.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose

Acknowledgments

The authors would like to show their gratitude to Duse M., Minasi D., Miraglia Del Giudice M., Cardinale F., Caffarelli C., Calvani M., Martelli A., Pajno GB., Tosca M., Manti S as members of the governing board of the Italian Society of Pediatric Allergology and Immunology (SIAIP) and thank the reviewers for their insights.

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

- 1. Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, Rubens C, Menon R, Van Look PF. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ.2010;88:31–8.
- 2. Zeitlin J, Mohangoo AD, Delnord M, Cuttini M, The EURO-PERISTAT Scientific Committee. The second European Perinatal Health Report: documenting changes over 6 years in the health of mothers and babies in Europe. J Epidemiol Community Health.2013;67:983-5
- 3. Ministero della Salute. Certificato di assistenza al parto. In: Analisi dell'evento nascita; 2012, http://www.salute.gov.it/imgs/C 17 pubblicazioni 1731 allegato.pdf (Accessed August 2013).

- 4. Woodward LJ, Moor S, Hood KM, et al. Very preterm children show impairments across multiple neurodevelopmental domains by age 4 years. Arch Dis Child Fetal Neonatal Ed 2009;94:F339–44.
- 5. Dall'Oglio AM, Rossiello B, Coletti MF, Bultrini M, DE Marchis C, et al. Do healthy preterm children need neuropsychological follow-up? Preschool outcomes compared with term peers. Dev Med Child Neurol.2010;52(10):955–61.
- 6. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet.2008;371:261–9.
- 7. Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines.2011;10:175–86
- 8. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol.2012;2012:985646.
- Siegrist CA, Córdova M, Brandt C, Barrios C, Berney M, Tougne C, Kovarik J, Lambert PH. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine.1998;16:1409–14.
- 10. Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. Arch Dis Child.2006;91:929–35.
- 11. Lawn JE, Osrin D, Adler A, Cousens S. Four million neonatal deaths: counting and attribution of cause of death. Paediatr Perinat Epidemiol.2008;22:410–6.
- 12. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics.2002;110:285–91.
- 13. Langkamp DL, Davis JP. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr.1996;128:654–9.
- 14. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J.2002;21:182–6.
- 15. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep. 2018;67:1-20.
- Pickering LK, Baker CJ and Kimberlin DW, Preterm and low birth weight infants. In Red Book 2012, Report of the Committee on Infectious Diseases. 29th Edition ed Elk Grove Village, IL: American Academy of Pediatrics.2012.p 69–71.
- 17. American Academy of Pediatrics (2015). Red book online: Immunization in preterm and low birth weight infants. Retrieved from http://redbook.so lutions.aap.org/chapter.aspx?sectionId=88187007&bookId= 1484&resultClick=1 on 20 April 2016.
- Australian Government (2016). The Australian immunisation handbook; Groups with special vaccination requirements. Retrieved from http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Conte nt/Handbook10-home~handbook10part3~handbook10-3-3#3-3-2 on 20 April 2016
- 19. Davis RL, Rubanowice D, Shinefield HR, et al. Immunization levels among premature and low-birthweight infants and risk factors for delayed up-to-date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group. JAMA.1999;282:547–53.
- 20. Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL et al. Vaccination of special populations: Protecting the vulnerable. Vaccine. 2016;34:6681-90.
- 21. Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics.2003;112:193-8.
- 22. Sisson H, Gardiner E, Watson R, Vaccination timeliness in preterm infants: An integrative review of the literature. J Clin Nurs.2017;26:4094–104.
- 23. Woestenberg PJ, van Lier A, van der Maas NA, Drijfhout IH, Oomen PJ, de Melker HE. Delayed start of diphtheria, tetanus, acellular pertussis and inactivated polio vaccination in preterm and low birth weight infants in the Netherlands. Pediatr Infect Dis J.2014;33:190-8.
- 24. Gad A, Shah S. Special immunization considerations of the preterm infant. J Pediatr Health Care.2007;21:385-91.

- 25. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: Causes, consequences, and a call to action. Vaccine.2015;33:D66-71.
- 26. Batra SJ, Eriksen EM, Zangwill KM, Lee M, Marcy SM et al, Evaluation of Vaccine Coverage for Low Birth Weight Infants During the First Year of Life in a Large Managed Care Population. Pediatrics.2009;123:951–958
- 27. Crawford NW,Yeo V, Hunt RW, Barfield C, Gelbart B et al. Immunisation practices in infants born prematurely: Neonatologists' survey and clinical audit. Journal of Paediatrics and Child Health.2009;45:602–60.
- 28. Denizot S, Fleury J, Caillaux G, V. Rouger V, Rozé J-C et al, Hospital initiation of a vaccinal schedule improves the long-term vaccinal coverage of ex-preterm children. Vaccine.2011;29: 382–86.
- 29. Cerutti M, De Lonlay P, Menni F, Parini R, Principi N, Esposito S. Vaccination coverage of patients with inborn errors of metabolism and the attitudes of their parents towards vaccines. Vaccine.2015;33:6520-4.
- 30. Tozzi AE, Piga S, Corchia C, Di Lallo D, Carnielli V et al, Timeliness of routine immunization in a population-based Italian cohort of very preterm infants: Results of the ACTION follow-up project. Vaccine 2014; 32:793–99.

An evaluation of the coverage and timeliness of routine immunizations assessing the determinants of immunization delay in a large, prospective area-based Italian cohort of VPI followed up at 2 years of age

- 31. Moss SJ, Fenton AC, Toomey JA, Grainger AJ, Smith J, Gennery AR. Responses to a conjugate pneumococcal vaccine in preterm infants immunized at 2, 3, and 4 months of age. Clin Vaccine Immunol.2010;17:6–1810.
- 32. Vázquez L, Garcia F, Rüttimann R, Coconier G, Jacquet JM, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr.2008;97:9–1243.
- 33. Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, et al. Recurrent apnoea post immunisation: informing re-immunisation policy. Vaccine.2011;29:7–5681.
- 34. Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist CA. Recurrence of cardiorespiratory events following repeat DTaP-based combined immunization in very low birth weight premature infants. J Pediatr.2008;153:429–31.
- 35. Rückinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis.2010;10:12. doi: 10.1186/1471-2334-10-12.
- D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, Beeler JA.Measles– mumps–rubella and varicella vaccine responses in extremely preterm infants. Pediatrics.2007;119:9–574.
- 37. Schulzke S, Heininger U, Lücking-Famira M, Fahnenstich H. Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. Eur J Pediatr.2005;164:5–432.
- 38. Faldella G, Galletti S, Corvaglia L, Ancora G, Alessandroni R. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants. Vaccine.2007;25:1036-42.
- 39. Lee J, Robinson JL, Spady DW. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. BMC Pediatr.2006;6:20.
- 40. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. Plos Medicine.2009; 6:1-28.
- 41. Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R, Oomori S et al. Effect of early measles vaccination (AIK-C strain) for preterm infants. Pediatr Int.2013;55:163-8.
- 42. Saroha M, Faridi MM, Batra P, Kaur I, Dewan DK. Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31-33 weeks) infants. Hum Vaccin Immunother.2015;11:2864-71

- 43. Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Thøstesen LM, et al. Bacillus Calmette-Guérin vaccination at birth: Effects on infant growth. A randomized clinical trial. Early Hum Dev.2016;100:49-54
- 44. Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Foss KT, Thøstesen LM et al. Lack of a Negative Effect of BCG-Vaccination on Child Psychomotor Development: Results from the Danish Calmette Study A Randomised Clinical Trial. PLoS One.2016;11:e0154541.
- 45. Roué JM, Nowak E, Le Gal G, Lemaitre T, Oger E et al, Impact of Rotavirus Vaccine on Premature Infants. Clinical and Vaccine Immunology.2014;21:1404-09.
- 46. Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93.
 *An assessment of the safety, reactogenicity and immunogenicity of rotavirus vaccine in European preterm infants by a prospective randomized, double-blind placebo-controlled
- multicentre trial*.
 47. Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, Seki K et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int.2012;54:64-7.
- 48. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D et al. Influenza A/H1N1 MF59adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics.2011;127:e1161-8.

A prospective randomized study about immunogenicity and safety of a monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine involving children aged 6 to 23 months of different gestational age

- 49. Kent A, Ladhani SN, Andrews NJ, Scorrer T, Pollard AJ, Clarke P et al. Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. Pediatrics.2016;138: e20153945-56.
- 50. Klein NP, Gans HA, Sung P, Yasukawa LL, Johnson J, Sarafanov A et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis. 2010;201:214-22.
- McCrossan P, McCafferty C, Murphy C, Murphy J. Retrospective review of administration of childhood primary vaccination schedule in an Irish tertiary neonatal intensive care unit. Public Health.2015; 30:1-3
- 52. Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5.
- 53. Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM et al. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. Pediatr Infect Dis J.2011;30:e216-24.
- 54. Omeñaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, Kafetzis D et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics.2011;128:e290-8.

An evaluation of safety and immunogenicity of the 10-valent pneumococcal non typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in preterm infants of different gestational age.

- 55. Wilińska M, Warakomska M, Głuszczak-Idziakowska E, Jackowska T. Risk factors for adverse events after vaccinations performed during the initial hospitalization of infants born prematurely. Developmental Period Medicine. 2016;20,296-305.
- 56. Anderson J, Noori K and Morris SA. Apnoea after the 2-month immunisation in extremely preterm infants: What happens with the 4-month immunisation? Journal of Paediatrics and Child Health.2013;49: E217–E220
- 57. Furck AK, Richter JW and Kattner E. Very low birth weight infants have only few adverse events after timely immunization. Journal of Perinatology.2010; 30:118–21
- 58. DeMeo SD, Raman SR, Hornik CP, Wilson C, Clark R et al. Adverse Events After Routine Immunization of Extremely Low Birth Weight Infants. JAMA Pediatr.2015; 169: 740–45.
- 59. Hacking DF, Davis PG, Wong E, Wheeler K, McVernon J. Frequency of respiratory deterioration after immunisation in preterm infants. Journal of Paediatrics and Child Health.2010; 46:742–8

- 60. Klein NP, Massolo ML, Greene J, Dekker CL, Black S. Risk Factors for Developing Apnea After Immunization in the Neonatal Intensive Care Unit. Pediatrics.2008;121:463-9.
 An assessment of factors associated with postimmunization apnea using multivariate logistic regression in a cohort of infants immunized in the NICU.
- 61. Carbone T, McEntire B, Kissin D, Kelly D, Steinschneider A, Violaris K et al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics.2008;121:e1085-90.

* The only prospective, blinded, controlled, randomized, multicenter study reexamining the relationship between diphtheria-tetanus-acellular pertussis and cardiorespiratory events in preterm infants. *

- Ben Jmaa W, Hernández AI, Sutherland MR, Cloutier A, Germain N, Lachance C et al. Cardiorespiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study. Pediatr Infect Dis J.2017;36:988-94.
- 63. Faridi M, Kaur S, Krishnamurthy S, Kumari P. Tuberculin conversion and leukocyte migration inhibition test after BCG vaccination in newborn infants. Hum Vaccin.2009;5:690-5.
- 64. Ferreira CSM, Perin MCAA, de Moraes-Pinto MI, Simão-Gurge RM, Goulart AL et al. Humoral immune response to measles and varicella vaccination in former very low birthweight preterm infants. Braz J Infect Dis.2018. 22:41-46
- 65. Szynczewska E, Chlebna-Soko D. Immunogenicity of Heptavalent Conjugate Vaccine Against Streptococcus pneumoniae in Premature Babies with Low Birth Weight. Pediatrics and Neonatology.2014; 55:101-7.
- 66. Van den Berg JP, Westerbeek EAM, Van der Klis, Sanders EAM, MD, Berbers GAM et al. Response on Pneumococcal Vaccine in Preterm Infants After Neutral and Acidic Oligosaccharides Supplementation. The Pediatric Infectious Disease Journal.2015; 34: 976:82.
- 67. Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, Omeñaca F et al. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants. Pediatr Infect Dis J.2017;36:326-332.
- 68. Rückinger S, Van der Linden M, Von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infectious Diseases.2010;10:12-6.
- 69. Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6-23 months over multiple seasons. Vaccine.2013;31:2974-8.

An evaluation of the effectiveness of seasonal influenza vaccination in all pre- and full-term in a large population study

- 70. Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, Locht C et al. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine.2013;31:1981-6.
- 71. Hviid A. Effectiveness of two pertussis vaccines in preterm Danish children. Vaccine.2009;27:3035-8.

*A nationwide cohort study of 879,424 Danish children about effectiveness of pertussis vaccination, both whole-cell and acellular in preterm and full-term children. *

- 72. Baxter D, Ghebrehewet S, Welfare W, Ding DC. Vaccinating premature infants in a Special Care Baby Unit in the UK: results of a prospective, non-inferiority based, pragmatic case series study. Hum Vaccin.2010;6:512-20.
- 73. Omeñaca F, Garcia-Sicilia J, Boceta R, García-Corbeira P. Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine. Infect Dis Obstet Gynecol.2010;2010:802503.
- 74. Adam D, Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine coadministered with routine vaccine combinations. Vaccine.2008;26:5944–51

- 75. Shinefield H,Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccinein low birth weight and preterm infants. Pediatr Infect Dis J.2002;21:182–6
- 76. Omeñaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics.2005;116:1292–98
- 77. Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga Hernando A, Garcia-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J.2007;26:824–9
- 78. Pfister RE, Aeschbach V, NiksicStuber V. Safety of DtaP based combined immunization in very low birth weight premature infants frequent but mostly benign cardiorespiratory events. J Pediatr.2004;145:58-66.
- 79. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.2000; 49:1e35.
- 80. Esposito S, Fumagalli M and Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines.2012;11:1199–209.
- Robinson CL, Bernstein H, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2019. Weekly 2019; 68:112–4.
- 82. Armstrong C, Practice Guidelines: AAP Updates Guidelines on Rotavirus Vaccination. Am Fam Physician. 2010;81:552-53.
- 83. National advisory committee on immunization. Litterature review on Rotavirus: disease and vaccine characteristics. Can commun Dis Rep 2010; 36:1-31.
- 84. Immunisation against infectious disease (the Green Book) <u>www.gov.uk/government/publications/rotavirus-the-green-book-chapter-27b</u>.Ref: PHE publications gateway number 2018748

Table and figure legends

 Table 1: PRISMA 2009 Checklist filled out [40].

Table 2: Sixty-one articles identified with the search details (infant, preterm"[MeSH Terms]) AND

 "vaccination"[MeSH terms] and exclusion criteria for the screening relying on studies' abstracts or titles.

Table 3: Studies regarding vaccine safety in preterm infants.

[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV=PCV10-non typeable H.influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II); AOR=adjusted odd ratio; CI=confidence interval].

Table 4: Studies regarding vaccine immunogenicity in preterm infants

[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV=PCV10-non typeable H. influenzae protein D conjugate vaccine; FHA=filamentous haemagglutinin; PT=pertussis toxin; PRN=pertactin; OPA=opsonophagocytic activity; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test; SBAMenC=seroprotective serum bactericidal activity thresholds against meningococcal serogroup C vaccine].

Table 5: Studies regarding vaccine effectiveness in preterm infants.

[Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV=PCV10-non typeable H. influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test, IC=interval confidence; ED=emergency department; HR= Adjusted hazard ratios; Pw=pertussis whole vaccine; Pa=pertussis acellular vaccine].

Figure 1: Four-phase flow diagram of the systematic review in accordance with PRISMA guidelines [40].

Section/topic	#	Checklist item	Reported on page #		
TITLE	I.				
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1		
ABSTRACT					
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.			
INTRODUCTIO	N				
Rationale	3	Describe the rationale for the review in the context of what is already known.	1		
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	2		
METHODS					
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Not applicable		
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow- up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3		
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3		
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	3		
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	3 Table 2 Figure 1		
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	3		
Data items					
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	3 Table 3-5		

Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Not applicable
Synthesis of results		Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Not applicable

		-	
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	3 Table 3-5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Not applicable
RESULTS	•		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	3-4
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	4-13 Table 3-5
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	4-13 Table 3-5
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Table 3-5
Synthesis of results	21	Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of consistency" in accordance with the text in the Explanation and Elaboration document.	Not applicable
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Table 3-5
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Not applicable
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the	16

systematic review.	

Table 1: PRISMA 2009 Checklist filled out [40].

References	Excluded/	Reason	
	included		X
Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L et al.	Excluded	Review	
Immunization of preterm infants with GSK's hexavalent combined	Entradua		
diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-			
Haemophilus influenzae type b conjugate vaccine: A review of safety and			
immunogenicity. Vaccine. 2018;36:986-96.			
Ferreira CSM, Perin MCAA, Moraes-Pinto MI, Simão-Gurge RM, Goulart	Included		
AL et al. Humoral immune response to measles and varicella vaccination in	(immunogenicity)		
former very low birth weight preterm infants. Braz J Infect Dis.2018;22:41-6.	¢ 0 ,,		
[64]			
Sisson H, Gardiner E, Watson R. Vaccination timeliness in preterm infants:	Excluded	Review	
An integrative review of the literature. J Clin Nurs.2017:26;4094-104.			
Cuna A, Winter L. Quality Improvement Project to Reduce Delayed	Excluded	Not pertinent	
Vaccinations in Preterm Infants. Adv Neonatal Care.2017;17:245-49.			
Wilińska M, Warakomska M, Głuszczak-Idziakowska E, Jackowska T. Risk	Included		
factors for adverse events after vaccinations performed during the initial	(safety)		
hospitalization of infants born prematurely. Dev Period Med.2016;20:296-			
305. [55]			
Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E,	Included		
et al. Circulating Antibody 1 and 2 Years After Vaccination With the 13-	(immunogenicity)		
Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term			
Infants. Pediatr Infect Dis J.2017;36:326-32. [67]			
Kucukoglu S, Aytekin A, Celebioglu A, Celebi A, Caner I, et al. Effect of	Excluded	Not pertinent	
White Noise in Relieving Vaccination Pain in Premature Infants. Pain Manag		-	
Nurs.2016;17:392-400.			
Kent A, Ladhani SN, Andrews NJ, Scorrer T, Pollard AJ, et al. Schedules for	Included		
Pneumococcal Vaccination of Preterm Infants: An RCT.	(immunogenicity		
Pediatrics.2016;138:e20153945-58[49]	and safety)		
Kilich E, Sadarangani M. Use of rotavirus vaccines in preterm babies on the	Excluded	Not pertinent	
neonatal unit. Expert Rev Vaccines.2016;15:1463-65.			
Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Thøstesen LM, et al.	Included		
Bacillus Calmette-Guérin vaccination at birth: Effects on infant growth. A	(safety)		
randomized clinical trial. Early Hum Dev.2016;100:49-54 [43]			
Higgins RD, Shankaran S. The Neonatal Research Network: History since	Excluded	Not pertinent	
2003, future directions and challenges. Semin Perinatol.2016;40:337-40.			
Olsen SJ, Mirza SA, Vonglokham P, Khanthamaly V, Chitry B et al. The	Excluded	Not pertinent	
Effect of Influenza Vaccination on Birth Outcomes in a Cohort of Pregnant			
Women in Lao PDR, 2014-2015. Clin Infect Dis.2016;63:487-94.			
Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Foss KT et al. Lack of a	Included		
Negative Effect of BCG-Vaccination on Child Psychomotor Development:	(safety)		
Results from the Danish Calmette Study - A Randomised Clinical Trial.			
PLoS One.2016;11:e0154541. [44]			
Navarro-Alonso JA, Taboada-Rodríguez JA, Limia-Sánchez A; Toward a	Excluded	Review	
New Immunization Schedule in Spain, 2016 (Part 2). Rev Esp Salud			
Publica.2016;90:E3.			
McArdle AJ, Mugisha G, Birahinduka D. QUESTION 2: Vaccinating	Excluded	Commentary	
preterm infants in resource-poor settings: what is the incidence of apnoea,			
bradycardia and need for respiratory support? Arch Dis Child 2016;101:290-			
3.			
Salamouras D, Levy J. Vaccination of premature infants, a population at high	Excluded	Review in French	
risk of infection. Rev Med Brux.2015;36:223-8			
Saroha M, Faridi MM, Batra P, Kaur I, Dewan DK. Immunogenicity and	Included		
safety of early vs delayed BCG vaccination in moderately preterm (31-33	(safety and		
weeks) infants. Hum Vaccin Immunother.2015;11:2864-71 [42]	immunogenicity)		
McCrossan P, McCafferty C, Murphy C, Murphy J. Retrospective review of	Included		
administration of childhood primary vaccination schedule in an Irish tertiary	(safety)		
neonatal intensive care unit. Public Health.2015;129:896-8.			1

Kille F. Authony M. Rotsvins vaccitation in preterm infants: a anomal generation of a timely immunistion. Arch Dis Child Feal Nonanal Feal No. 1997. Faculad Later Rd 2015 (100-166) Miller K. Uhench L. Bomer S. Jonchim A. Becker I, et al. Multidimensional fear Monana M. Children M. Miller K. Uhench L. Bomer S. Jonchim A. Becker I, et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim A. Miller K. Uhench L. Bomer S. Jonchim A. Becker I, et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim A. Becker I, et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim M. Becker I. et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim M. Becker I. et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim M. Becker I. et al. Multidimensional fear Miller M. Uhench L. Bomer S. Jonchim M. Becker I. et al. Multidimensional fear Miller Miller M. Miller M. Becker I. et al. Multidimensional fear Miller M. Mille				
public educt to all innel immunisation. Arch Die Child Feal Neuralal La 2015;1001-045. Meller K, Ubrich L, Borner S, Joschim A, Becker J, et al. Multidimensional response to vericuition pain in very printern. incedence to alse partnern and fall-arem infants auge there montes. Early Linn Der 2015;21:19-204 Chicha TJ, Zaw Van, Faustös R, Davidi C, Sakazar JA et al. Vaccine Facultad S, Paville D, Notaniao G, Marcine J, Berner LD, Vancine J, Sakazar JA, Berner J, Sakazar J, Sak	Kilich E, Anthony M. Rotavirus vaccination in preterm infants: a neonatal	Excluded	Letter	
FL2015(10)F465. Fixeducial Fixeducial Robber K, UHORD, H, Romer S, Joachim A, Backer J, et al. Multidimensional Fixeducial Fixeducial Robber K, UHORD, J, Romer S, Joachim A, Backer J, et al. Vaccime Excluded Not pertinent Robber K, UHORD A, Marka RD, Davin C, Salazz JA et al. Vaccime Excluded Not pertinent Robber K, UHORD A, Vaccimation Opticerum infants by Fixeducial Review Period Med2014.18:3606. Review of Interactic Dev Review Period Med2014.18:3606. Review of Interactic Dev Review Period Med2014.18:3606. Review control of the anomal term and perterm infant-mobber pairs in Turkey, a courny where material and normal terms and control terms have creatry been Not pertinent Intracts, exist of Robin Social D, Carmelit V et al. Timeliness of Excluded Not pertinent Infants: results of Robin Social D, Carmelit V et al. Timeliness of Excluded Not pertinent Vaccima E, BL 2014.3174.3190.8 D. Carmelit V et al. Timeliness of Excluded Not pertinent Vaccima E, BL 2014.3174.3190.4 D. Carmelit V et al. Timeliness of Excluded Not pertinent Vaccima E, Stranger K, Kwang CC, Dack ST et al. On- times vaccimation in perton work of the pertonential in the Netherhands. Foreital All Part Stral All Part Str				
response to vaccination pain in very preterm, moderatio-to-late preterm and full-term inflams using there months. Early Hum Dev. 2015;11:99-204 Not pertinent Oches J1, Zao-Vera A, Buatsia R, Davile C, Salazzi AJ et al. Vaccine schedule complexements are your whith weight inflams in Linna. Peru. Excluded Not pertinent Vaccine 2015;33:354-8 Cargias H, EurotAB R, Bwalk D, Vaccination of preterm inflams by polyalent vaccines: immungenetity and safety: review of literature. Dev Period Med 2014;83:6040 Excluded Not pertinent diplohesit immonity arong giona and present inflams induced preterm inflams: needlo of phylonic inflam Coher pairs in inflams: needlo of phylonic inflam Coher pairs in inflams: needlo of phylonic inflams in the Netherlanda. Excluded Not pertinent Sayaccewski E, Chlebaa-Sokid D, Immunogenicity Of Perivaelant conjugate vaccincia giant Stropbecceus ppscure inflams in mink regenetic balies with low birth weight. Peduat Necatal 2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;				
response to vaccination pain in very preterm, moderatio-to-late preterm and full-term inflams using there months. Early Hum Dev. 2015;11:99-204 Not pertinent Oches J1, Zao-Vera A, Buatsia R, Davile C, Salazzi AJ et al. Vaccine schedule complexements are your whith weight inflams in Linna. Peru. Excluded Not pertinent Vaccine 2015;33:354-8 Cargias H, EurotAB R, Bwalk D, Vaccination of preterm inflams by polyalent vaccines: immungenetity and safety: review of literature. Dev Period Med 2014;83:6040 Excluded Not pertinent diplohesit immonity arong giona and present inflams induced preterm inflams: needlo of phylonic inflam Coher pairs in inflams: needlo of phylonic inflam Coher pairs in inflams: needlo of phylonic inflams in the Netherlanda. Excluded Not pertinent Sayaccewski E, Chlebaa-Sokid D, Immunogenicity Of Perivaelant conjugate vaccincia giant Stropbecceus ppscure inflams in mink regenetic balies with low birth weight. Peduat Necatal 2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;32:193-2014;		Excluded	Not pertinet	
full-term infants at age there months. Early Hum Dev. 2015;91:199:204 Cohen 17, Zeev Pen A. Buatis R. David C. Salazar M et al. Vescine Excluded Not pertinent Schedul C. Salazar M et al. Vescine Excluded Review Period Med.2014;18:360-6 Eterner-Encar T. Ashan M. Varill M. Erginoz E. Koozzybek B et al. Tetunus and diphthetia immunity atoms due notant tetunus haves recently been Crimeria Penet T. Ashan M. Varill D. Cambiolitik V et al. Timaliness of ranket, a county where material and notant tetunus haves recently been Crimeria Penet T. Scottar C. D. 11:10: D. Cambillitik H. Ostar 2017;27:279:19 Not pertinent Not pertinent Penied Med.2014;13:30-44 Not pertinent Not pertinent Penied Liphthetia tetamos and macronol 2017;27:279-9 Not pertinent Not pertinent Penied Makin No. Phythetia H. Ostar 2017;27:279-9 Not pertinent Not pertinent Penied Table No. Phythetia H. Ostar 2017;27:29-9 Not pertinent Penied Liphthetia tetamos and macronol 2014;27:279-19 Not pertinent Penied Liphthetia tetamos A. Ottifutamos H. H. Ostaro, M. Phythetia and C. Schuld K. Schul			- · · · P · · · · · · ·	
Ochen ZT, Zar-Vera A, Bautian R, Davila C, Saltzar JA et al. Vaccine schedule compluses annog very low birth weight infinits in Linna, Peru. Vaccine 2015;33:354-8. Excluded Not pertinent Capika H, Lantchade R, Pawik D. Vaccination of preterm infants by polyvalent vaccines. immungenicity and safety: review of literature. Dev Period Med 2014;18:30-06. Review Review Frend Med 2014;18:30-06. Excluded Not pertinent Not pertinent Infancts. Jan. J. Pedata: 2014;17:14:30-07. Excluded Not pertinent Infancts. Jan. J. Pedata: 2014;17:14:30-07. Excluded Not pertinent Infants: result of pedata: 2014;17:14:30-07. Excluded Not pertinent Infants: result of pedata: 2014;17:14:30-07. Excluded Not pertinent Infants: result of pedata: 2014;17:14:30-07. Excluded Not pertinent Very complexity: A list A, van der Mass NA. Drijfbourt H, Ornex P i at 1 Excluded Not pertinent Delay data: of driphten: statuas: acclular pertuss and materivity dipublic with weight infants in the Netherlands. Fedata: file 10:14:15:14:14:14:14:14:14:14:14:14:14:14:14:14:				
schedule compliance among very low birth weight infants in Lina, Peru. Vacence.2015/3314-8. Review Czajka II, Lauterbach R, Pawlik D. Vascination of preterm infants by polyvalent vaccines: immunogenicity and afcity- review of literature. Dev Review Period Med2014.18.360-6 Ferener-Enant T, Adam M, Varni M, Erginoz E, Koseazeybek B et al. Tetanus and anotatid tetans have recently been eliminated and notatid tetans have recently been eliminated and notatid tetans have recently been eliminated. Fur J Pedata 2014;17:439-44 Not pertinent Toziri AE, Pieja S, Corchia C, Di Latio D, Camielli V et al. Timeliness of routine immunization in a population-based finale cohort of very peterm infants: neuko 10:44:277-39.4 Excluded Not pertinent Westenderg PJ, un Lar A, van der Maax NA, Dijiloon III, Osmen PJ et al. Excluded Not pertinent Vergint Pedatar Neight infants in the Netherhands. Feature Intel Di 2014;33:100-8 Feature Intel Di 2014;33:100-8 Symacswale F, Lobhons Skolt D. Immunogenicity of bepravalent conjugate macing against Streptococcus pacamonates in premature lables: with low lath for manologing the feature over on all full-term thilden agade 6-23 Included (effectiveness) from and peterimination against streptococcus pacamonates in premature lables: with low lath for the observed streptococcus pacamonates in premature lables: Gain 2013;11:1101-102 Included (effectiveness) for the observed streptococcus pacamonates in premature lables: Gain 2013;11:1101-102 Weins K, Hawkers B, Hold Henningson, K. Kuong Z, Docks SI. et al.		Excluded	Not pertinent	
Vacence 2015/31354-8. Procession 2015/31354-8. Copils H, Landraba R, Pawik D. Vacenation of preterm infants by polyvalent vacentes: immunogenicity and safety-review of literature. Dev Periol Met2014 (18:30-6). Review Frence F, Fran T, Aslan M, Vural M, Frgino F, Koeazystek R et al. Tetnus and dipthetica in an opulation and preterm infant-mother pairs in function. J. Podiat.2014;17:339-44. Not pertinent Tozzi AE, Figa S, Corchin C, Di Lallo D, Carnell V et al. Timeliness of routine immunization in a population-based linkin cohort of very preterm infant: results of the ACTION follow-up project. Vacence 2014;27:273-9. Excluded Not pertinent Vosetherbig PJ, van Ler AY, van de Mass NA, Ejfichout III, Ournen PJ et al. Delayed start of diphtherin. tetams. acellular pretraiss and mactivated polo- vacennae agains Streptococces pneumonine in premature babies with low birth (immunogenicity) Included Not pertinent, Delayed P, delaw routine 2014 (27:27): D10-17 (ES). Spracewska E, Chobans-Soko D. Immunogenicity of heptavalent conjugate vacence agains Streptococces pneumonine in premature babies with low birth (immunogenicity) Included Not pertinent Witten K, Hawken S, Hodd Hemingsen K, Kwong JC, Dack S H et al. Druce the etain 2012 (20:25):0-12 Included Included Witten K, Hawken S, Hodd Hemingsen K, Kwong JC, Dack S H et al. Druce the etain 2012 (20:25):0-2 Included Included Witten K, Hawken S, Hodd Hemingsen K, Kwong JC, Dack S H et al. Druce vacerination and objeoint 2013 (20:27):0-10 <t< td=""><td></td><td>Excluded</td><td>Not pertinent</td><td></td></t<>		Excluded	Not pertinent	
Czajka H, Lauterbook R, Pavik D. Vaccination of preterm infants by polyvalet vaccins: immunogenicity and safety- review of literature. Dev Period Med 2014;18:300-6 Excluded Review Period Med 2014;18:300-6 Excluded Not pertinent Enterer.Crear, 1, Adam M, Vani M, Erginoz E, Koczacybek B et al. Tetama and diphtheria immunization in a population-based lutian cohort of very preterm infants: results of phtherin, tetama, seclular pertussis an inactivated policity Excluded Not pertinent Industr. Fitter M, Cortino C, Dia Libo D, Camriell W et al. Timeliness of nutine immunization in a population-based lutian cohort of very preterm infants: results of phtherin, tetama, scellular pertussis an inactivated policity Excluded Not pertinent Synaczwski R, Chichen Schöld D, Immunogenicity of heptavalent conjugate vaccine agains Kreptococcus procurs of the New herit weight. Pediatr Necotas 2014;32:193-8. Included Not pertinent Synaczwski R, Chichen Schöld D, Immunogenicity of Keynavlen Conjugate vaccine agains M, Catzvara A, Guttmann A, Kwong JC, Decks SI et al. On- tione vaccination cortexage in promannic in promannic coparation, 2002;2002 Can 1 Freudodt Freudodt Wrisen K, Hawken S, Hold Harvingsen K, Kwong JC, Decks SI et al. On- tione vaccination cortexage in promannic in promannic coparation of the co- different vaccines and effect of a booster dose. Vaccine. 2013;1:193-61(0) Freudodt Included Wrisen K, Hawken S, Hold Harvingsen K, Kwong JC, Decks SI et al. On- tione vaccination ocrteage in promannot inform momerspheres di	1 0 1 0			
polyvalent vaccines: immunogenicity and safety- review of fittrature. Dev Periad Met.2014;8:360-6 Erenser-Etexan T, Aslan M, Vural M, Erginoz E, Kocazaylek B et al. Tetanus and dipthetis immunity among terms and preterm infant-nother pairs in Turkey, a country where maternal and neonatal letima have recently been diminated. Eur Pediatr. 2014;17:439-44 Tozzi A&, Piga S, Corchiel C, Di Lallo D, Camielli V et al. Tuncliness of Toutne immunization in a population-based finlain cohord or vary peterm infants: results of the ACTION follow-up project. Vaccine 2014;32:793-94 Woostenberg PJ, vun Lier A, van der Mans NA, Drijbuo III, Oomen PJ et al. Delayed start of diptherin, tetanus, acellular pertussis and inactivated polio vaccination in preterm and low brith weight infants in the Nicherlands. Pediatt Infect Dis J.2014;33:109-8. Syncewska F, Chehna Sokoh D. Immunogenicity of heptavalent conjugate Vaccine against Struptococcus pneumonics in premative balves with low brith weight. Pediatt Neonol.2014 Apres 2011;31:2794-84 [60] Missing K, Hawken S, HoldH Homingen K, Kowing JC, Docks II et al. On- time vaccination coverage in premative infants in Onario.2002;2009. Con J Public Health 2012;10:259-862 Weimed M, Editar Struptococcus pneumonics in Onario.2002;2009. Con J Public Health 2012;10:259-862 Weimed M, Editar Struptococcus pneumonics in Onario.2002;2009. Con J Public Health 2012;10:259-862 Weimed M, Editar K, Strupto R, Castan R, et al. Effect of early Internative market and to coverage in preterm infants. Pediatt Intra-unogenicity) Immunogenicity) Results S, Fumagalli M, Principi N. Immunogenicity, safely and Iufertod for exposure misclassification using survival analysis with a time-varying exposure. Am Cliptolical Struptococcus 2013;11:1994-10[20] Elokiwa T, Tavika M, Funicipi N. Immunogenicity, safely and Iufer-ating infants after prinary immunization of hepreterm infants. Pediatt Intra-2013;51:163-8. Menus C, Schmadish G, Hamorstein S, Proquiti H, Rochr CC. Adverse Excluded Not written in english after prinary we			. .	
Period Med201418.306.6 Excluded Not pertinent and diphuberia immunity among term and preterm infant-mother pairs in Turkey, a contribution where meeting the meeting of the meeting the meeeing of the meeting of the meeting of the meeeing of the		Excluded	Review	
Izreare-Ercan T. Aslam M. Vural M. Epinozel, K. Goczaybek B et al. Telama and diphteria immunity among term and preterm infant-mother pairs in liminated. Eur J. Pediatr. 2014;174:339-44 Excluded Not pertinent Tozzy A, P. Pga S. Corchia C, Di Lallo D. Campilli V et al. Timeliness of routine immunization in a population-based lialian cohort of very preterm infants: results of the ACTION follow-up project. Vaccine 2014;32:793-94 Not pertinent Woestnober PJ, van Lier A, van der Mass NA. Dripiton III, Oomen PJ et al. Delayod start of diphteria, tetanas, acellular pertussis and imactivated polio vacenation in perterm and low birth weight infants in the Netherlands. Pediatr Infect Dis J.2014;33:106-8. Not pertinent Symczewska F, Clobhan S-kok DJ. Immunogenicity of heptavalent conjugate vaceine against Streptococcus pneuronice in premature babies with low birth weight. Pediatr effectiveness in me- and full-term infoldera agad 6-33 (effectiveness) (mmunogenicity) Wieson K, Hawkon S, Hohd Henningson K, Kwong JC. Deeks SL et al. On- time vaccination coverage in premature infants in Ottario, 2002-2009. Can. J Public heidsh. Doster does. Vaccin: 2013;31:198-167-1070 Included (infigumangenicity) Vertmenten F, Dirix V. Vaescheure V, Danis E, Verneylen D, et al. Persistence at one syster disc of antige-miduced callular immune responses in pretorm infants vaceinated against whooping cough: comparison of three different vaccination (Mic-C strain) for pretorm infants. Flopter d early measles vaccination (Mic-C strain) for pretorm infants. Flopter JC 1071 Included (safety) Abrens K, Lash TL, Louk C, Mitchell AA. Weiter MM, Gorecoting for exposure micfandsR G, Hamerstein N, Stropg				
and diphtheria immunity among term and preterm inflant-moder pairs in Turkey, a country where material and neonatal tetrans have recently been eliminated. Eur J Pediatr 2014;174:339-44 Tozzi A.F. Piga S. Corcha C. D. Laldo D., Carnielli V et al. Timeliness of routine immunization in a population-based lalian cohort of very preterm inflants: results of the ACTION follow-up project: Vary creatern liminatis results of the ACTION follow-up project: Vary preterm inflants: results of the ACTION follow-up project: Vary for heativatent conjugate vaccine against Stroptococcas pneuronione in premature bables with low birth (mmunogenicity) weight. Pediatr Neonatol 2014 Apr:55(2):101-7 [65] When K. Hawken S. Hold Homingen K. Kwong JC. Decks SI. et al. On- time vaccination overgae in pre-and full-term children agade 6-23 months over multiple seasons. Varxen: 20133 12:924-84 [69] Whan K. Hawken S. Hold Homingen K. Kwong JC. Decks SI. et al. On- time vaccination overgae in pre-ansite inflants in Ontario. 2002-2009. Can 1 Public Health 2012;10::599-62 Vermedule F. Divis, V. Verschenev V. Dumit E. Vermeylen D. et al. Effect of early in preterm inflant, a Fujino M, Kusano R. Sugiyann R et al. Effect of early in preterm inflant, fujino M, Kusano R. Sugiyann R et al. Effect of early in preterm inflants. Fugett Rev. Vaccine. 2013;11:981-61 [20] Included (safety) following 2-month vaccination gaing anviorial and ya8 with a time-varying exposure. Ann Epidemiol. 2012; 2:399-60 Marens K. Lash TL, Louik C, Mitchell AA, Weier MM. Greening for exposure michalischican using survival and ya8 with a time-varying exposure inflantifies R. Succideced of a shored redue verifies for english Merina V. Cashinake S. Houter C. Applier J. Harmanogenicity, 2:48-93 Anrens K., Lash TL, Louik K., Muiter M, Meren MM. Correcting for exp				
Turkey, a country where maternal and neonatal tetanus have recently been iminated. Eur. Pediatr. 2014;174:39-44 Tozzi ALE, Piga S, Corchia C, Di Lallo D, Camrelli V et al. Timeliness of Excluded Not pertinent infants: results of the ACTION follow-up project. Vaccine.2014;22:793-9. Excluded Not pertinent woestenberg PJ, van Lier A, van der Mass NA, Drijbur III, Oomen PJ et al. Excluded Not pertinent Vesciention PJ, van Lier A, van der Mass NA, Drijbur III, Oomen PJ et al. Excluded Not pertinent Symcrewska F, Chelhan Sokoh D. Immunogenicity of the Mark NA, Drijbur III, Oomen PJ et al. Excluded Not pertinent Symcrewska F, Chelhan Sokoh D. Immunogenicity of the Mark NA, Drijbur II, Oomen PJ et al. Excluded Not pertinent Wisnon K, Hawken S, Hohd Hernmegen K, Kwong JC, Deeks SL et al. Included Included Prosificer at ethic mark S. Hohd Hernmegen K, Kwong JC, Deeks SL et al. Included (safety instrument infants in Ontario, 2002;2009. Can.1 Public Heaht Doster dose: Vaccinc. 2013;31:1914. Included (safety instrument infants. Expert Qui J, 2014;1109- Included (safety instrument infants. Expert Qui J, 2014;1109- Included (safety instrument infants. Expert Rev Vaccinc.; 2017;41:1199- Not pertinent Vormeuler F, Dirix V, Verscheure V, Damis H, Perneyten D, et al. Persider Al on 2014;21	Erener-Ercan T, Aslan M, Vural M, Erginoz E, Kocazeybek B et al. Tetanus	Excluded	Not pertinent	
eliminated. Eur J Pediat 2014;174:339-44 Facehold frouzi AE, Paga S, Corebia C, Di Jallo D, Carnielli V et al. Timeliness of routine immunization in a population-based lualian cohort of very preterm infinits: results of the ACTEON follow-up project. Vaccin: 2014;32:793-9. Excluded Not pertinent Ubergot start of the ACTEON follow-up project. Vaccin: 2014;32:793-9. Excluded Not pertinent Point infect Dis 2014;33:100-8. Excluded Not pertinent Segnezowska E, Chlebna-Sokol D. Immunogenicity of heptivalent conjugate vaccine against Streptococcus proteomonic in premature bables with low birth veright. Pediatr Neonatol 2014;49:755(2):101-7 [65]. Included Segnezowska E, Chlebna-Sokol D. Immunogenicity of heptivalent conjugate uncine against Biot ACTEON and ACTEONE (Strept Streptococus proteine 2013;31:29748; [69]. Included Wilson K, Hawken S, Holdt Hemingson K, Kwong JC. Decks SI et al. On- time vaccinations overage in premature infants in Onlario. 2002;2009. Can J Public Health. 2012;10:783-62 Not pertinent Vermetulen F, Dirix V. Varscheure V. Damis E, Vermeylen D. et al. Previsione: and effect of a booster dose. Vaccine 2013;31:1981-6 [70] Included (minunogenicity) Indicator R, Laskin L, Louik C, Minchell AA, Weiler Md, Gorcecing for exposure instration. MK. Starason R, Stugiyana R et al. Effect of early In 2013;55:1644. Included Review 6490. Included infinition of adverse everis in premature children erglosio S, Famagalli M, P				
eliminated. Eur J Pediat 2014;174:339-44 Facehold frouzi AE, Paga S, Corebia C, Di Jallo D, Carnielli V et al. Timeliness of routine immunization in a population-based lualian cohort of very preterm infinits: results of the ACTEON follow-up project. Vaccin: 2014;32:793-9. Excluded Not pertinent Ubergot start of the ACTEON follow-up project. Vaccin: 2014;32:793-9. Excluded Not pertinent Point infect Dis 2014;33:100-8. Excluded Not pertinent Segnezowska E, Chlebna-Sokol D. Immunogenicity of heptivalent conjugate vaccine against Streptococcus proteomonic in premature bables with low birth veright. Pediatr Neonatol 2014;49:755(2):101-7 [65]. Included Segnezowska E, Chlebna-Sokol D. Immunogenicity of heptivalent conjugate uncine against Biot ACTEON and ACTEONAL (Internet Pacific Section 2013):12:9748. [69]. Included Wilson K, Hawken S, Holdt Herningson K, Kwong JC. Desks SI et al. On- time vaccinations overage in premature infants in Onlario. 2002-2009. Can. J Public Health. 2012;10::839-62 Not pertinent Vermetulen F, Dirix V. Varscheure V. Damis E, Vermeylen D. et al. Previsione: and effect of a booster dose. Vaccine. 2013;31:1981-6 [70] Included (impunogenicity) Indicator R, Laskin L, Louik C, Minchell AA, Weiler Md, Gorcecing for exposure instalfication sing survival analysis with a line-varying exposure. Ann Epidemiol. 2012; 22: 29:9860 Included Not written in english Vision K, Hawken S. Indicator of alwares everis in premature children f	Turkey, a country where maternal and neonatal tetanus have recently been			
Fourier immunization in a population-based failine cohord of very preterm infinits: results of the ACTEON follow-up project. Vaccin: 2014.32:739-9 Not pertinent Woestenberg PJ, van Lier A, van der Mats NA, Drijfhout III, Ommen PJ et al. Excluded Not pertinent Polary distro of diphteria, teamus acellular pertussis and inactivated polio vaccination in preterm and low birth weight infants in the Netherlands. Included Not pertused Polar Inferd Netonal 2014 App (52): 101-71 (53) Included (immunogenicity) Included (immunogenicity) Included Synczewska E, Chlebna-Sokół D. Immunogenicity of heptavalent conjugat Included (immunogenicity) Included (immunogenicity) Shen S, Campicelli MA, Catzavara A, Guttmann A, Kvong JC, Seasonal Included (immunogenicity) Included (immunogenicity) Wiston K, Hawken S, Itold H Tennigper K, Kwong JC, Deeks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can J Excluded (immunogenicity) Vermeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Excluded (immunogenicity) Included (affer) Presistence at ooseard oes V accine 2013;12:191-161 (70) Included (affer) Included (affer) Presistence at ooseard oes V accine 2013;12:191-161 (70) Included (affer) Included (affer) Postis K, Hawken S, Instelleneering in fintherentime tensors Included (affer) <td>eliminated. Eur J Pediatr.2014;174:339-44</td> <td></td> <td></td> <td></td>	eliminated. Eur J Pediatr.2014;174:339-44			
Fourier immunization in a population-based failine cohord of very preterm infinits: results of the ACTEON follow-up project. Vaccin: 2014.32:739-9 Not pertinent Woestenberg PJ, van Lier A, van der Mats NA, Drijfhout III, Ommen PJ et al. Excluded Not pertinent Polary distro of diphteria, teamus acellular pertussis and inactivated polio vaccination in preterm and low birth weight infants in the Netherlands. Included Not pertused Polar Inferd Netonal 2014 App (52): 101-71 (53) Included (immunogenicity) Included (immunogenicity) Included Synczewska E, Chlebna-Sokół D. Immunogenicity of heptavalent conjugat Included (immunogenicity) Included (immunogenicity) Shen S, Campicelli MA, Catzavara A, Guttmann A, Kvong JC, Seasonal Included (immunogenicity) Included (immunogenicity) Wiston K, Hawken S, Itold H Tennigper K, Kwong JC, Deeks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can J Excluded (immunogenicity) Vermeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Excluded (immunogenicity) Included (affer) Presistence at ooseard oes V accine 2013;12:191-161 (70) Included (affer) Included (affer) Presistence at ooseard oes V accine 2013;12:191-161 (70) Included (affer) Included (affer) Postis K, Hawken S, Instelleneering in fintherentime tensors Included (affer) <td>Tozzi AE, Piga S, Corchia C, Di Lallo D, Carnielli V et al. Timeliness of</td> <td>Excluded</td> <td>Not pertinent</td> <td></td>	Tozzi AE, Piga S, Corchia C, Di Lallo D, Carnielli V et al. Timeliness of	Excluded	Not pertinent	
infinits: results of the ACTION follow-up project. Vaccine 2014;32:793-9. Excluded Westenberg PJ, van Lie A, van der Mass NA, Driffhou HL, Oomen PI et al. Excluded Not pertinent Delayed start of diphteria, tetanus, acellular pertussis and inactivated polio Excluded Not pertinent Synczwska E, Chlebna-Skoh D. Immunogenicity of hoptavalent copugate Included (immunogenicity) synczwska E, Chlebna-Skoh D. Immunogenicity of hoptavalent copugate Included (immunogenicity) synczwska E, Chlebna-Skoh D. Immunogenicity of hoptavalent copugate Included (immunogenicity) syncarwska E, Chlebna-Skoh D. Immunogenicity of hoptavalent copugate Included (immunogenicity) syncarwska E, Chlebna-Skoh D. Immunogenicity of hoptavalent copugate Included (immunogenicity) weight - Pediat coversate in premature inflatis no notario. 2002-2009. Can 1 Excluded Not pertinent meta vaccinate digates weight of the science. 2013;31:2974-8 [69] Included (safety instrumone) (immunogenicity) Werneule F, Diaso Kauson R, Suggama R et al. Effect or ary In Included (safety instrumone) (immunogenicity) (immunogenicity) in present inflatis. Networs R et al. Effect or ary Include R eview (immunogenicity) (immunogenicity) chikkwa T			1	
Weetscherg PJ, van Lier A, van der Mais NA, Drijfhout HJ, Oomen PJ et al. Delayed start of diphheric, textmuss, acellular preusiss and inactivited polio vaccination in preterm and low hirth weight infants in the Netherlands. Pediatr Infect of diphheric, textmuss, acellular preusiss and inactivited polio vaccine against Strepost Course preumoniae in premature babies with low birth veight. Pediatr Neoratol 2014 Apr;55(2):101-7[65] Included (immunogenicity) Symczevska E, Chlebna-Skól D. Immunogenicity of heptavalent conjugate veight. Pediatr Neoratol 2014 Apr;55(2):101-7[65] Included (immunogenicity) Shen S, Camprielli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal (Inflexeta vaccine effectiveness) Included (immunogenicity) Wilson K, Hawken S, Hold Henningsen K, Kwong JC, Decks SL et al. On- time vaccination coverage in premature infants in Ontario. 2002-2009. Can J Pablic Health, New S, Hold Henningsen K, Kwong JC, Decks SL et al. On- time vaccination coverage in antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three (mmunogenicity) Eveluded Not pertinent endifferent vaccine and effect of abosef dose. Vaccine 2013;11:2918-16 [70] Ichlebded (Inferent vaccination (ALK-C strain) for preterm infants. Pediat in action;13:55:163-8. Review Review Papes SL, Labar TL, Louik C, Mitchell AA, Weeler MM, Gorrecting for exposure misclassification using survival analysis with a time-varying exposure. An Epidemiol. 2012; 2:799-800. Included (safety) following 2-month vaccination. Immunoder: 212: 8:92-5 [52] Zhang L, Zhai XJ, Li YP, Zhang W, Zhat PC, Huang T, et al. Multi-center matching study on anti				
Delayed start of diphteria, tetanus, acellular pertussis and inactivated polio vaccination in preterm and low linth weight infants in the Netherlands. Pediart Infect Dis J. 2014;33:190-8. Szynczewska E, Chlebna-Sokól D, Immunogenicity of heptavalent conjugate vacine against Streptococcus pneumoniae in premature bables with low birth vecight. Pediart Neonatol. 2014;Apr;53(2):101-7 [65] Included (immunogenicity) Shen S, Campfelli MA, Calzavara A, Guttmann A, Kwong JC, Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6-23 (immunogenicity) Included months over multiple seasons. Vaccine 2013;31:2974-8 [69] Wilson K, Hawken S, Holdti Henningsen K, Kwong JC, Decks SI, et al. On- Bzeudded Not pertinent Vermeulen F, Dirix V. Versiberure V, Damis E, Vermeylen D, et al. Included (safety in preterm infints vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013;31:1981-6/120] Included (safety inmunogenicity) Included (safety against Muchange Survival analysis with a time-varying exposure. Anni Epidemicity) Excluded Review 200. Ahrenes K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure inscienation. Ifum Agae: Infimumoter 2012;8:592.5 [2] Not written in english work on the correcting for exposure inscienation. Jum Agae: Infimumoter 2012;8:592.5 [2] 201m L, Louik C, Mitchell AA, Werler MM. Correcting for exposure inscinating study on antibody exponse baveen preterm and full-term infin	11 3	Excluded	Not nertinent	
vaccination in preferm and low birth weight infants in the Netherlands. Perlain Tinfer 015 J2014;31:190-8. Szynczewska E, Chlebna-Sokół D. Immunogenicity of heptavalent conjugate (immunogenicity) Included (immunogenicity) weight. Pediatr Neonatol 2014 Apr.55(2):101-71 (65] Included (immunogenicity) Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal (feftextveness) Included (iffectiveness) months over multiple seasons. Vaccine 2013;31:2974-8 [69] Not pertinent Public Health-West, 51 Hold Henningsen K, Kwong JC. Decks SL et al. On-time vaccination coverage in prenature infants in Ontario, 2002-2009. Cn 1 Excluded Not pertinent Public Health-West, 51 Hold Heange cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013;31:1981-6/100 Included (safety measles) Included (safety measles) Persistence at one year of age of antigen-induced cellular immune responses in pre-natrue infants. Nason R & Suguram R et al. Pfree of early measles vaccination (AlK-C stran) for preterm infants. Pediati immunogenicity) Included (safety measles) Included (safety measles) Lohkawa T, Fugi A, Fujino M, Kusano K, Sugura M, Gureireting for exposure misclassification using survival analysis with a time-varying exposure Anne pidemiol 2012 (22:799-806 Excluded Not pertinent english Wilson K, Hawken S, Incidence of advene eventis in premature children (minumogenicity) Excluded Not written in english Gaudelu		Excluded	Not pertinent	
Pediatr Infect Dis 1.2014/3:190-8. Included Synczewska E, Chlchan-Schöld D. Immunogenicity of heptavalent conjugate Included weight. Pediatr Neonatol 2014 Apr;55(2):101-7[65] Included Shen S, Campielli MA, Calavara A, Guttmam A, Kwong JC. Seasonal Included influenza vaccine effectiveness in pre- and full-term children aged 6-23 (effectiveness) months over multiple seasons. Vaccin: 2013;1:2974-8 [69] Not pertinent Wilson K, Hawken S, Holdt Henningen K, Kwong JC. Decks SI. et al. On- Excluded Not pertinent Persistence at one year of age of antigen-induced cellular immune responses Included (safety Included (safety measare synchronic and the Caratory in present infants vaccinated against whooging cough: comparison of three Included (safety Included (safety exposure Ann Epidemiol 2012; 22:7992806 Included (safety Included (safety) exposure Ann Epidemiol 2012; 22:7992806 Included (safety) Included (safety) Wilson K, Hawken S, Incidence of Adves evenis in premature children infinits Excluded Not written in fold muture infiniting study on antibody syspense bysins with a time-varying exposure infinition agenistify and tolerability Scluded Vilson K, Hawken S. Incidence of Adves evenis in premature childre				
Synzzewska E, Chelma-Sokol D. Immunogenicity of Peptavalent conjugate weight. Pediatr Neonatol.2014 Apr;55(2):101-7 [65] Included (immunogenicity) Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal Influenza vaccine effectiveness in pre- and full-term children aged 6-23 months over multiple seasons. Vaccine 2013;31:2974-8 [60] Included (effectiveness) Wilson K, Hawken S, Hold Henningsen K, Kwong JC, Deck S L et al. On- time vaccination coverage in premature infants in Onlario, 2002-2009. Can I Public Health Waken S, Hold Henningsen K, Kwong JC, Deck S L et al. On- time vaccination coverage in premature infants in Onlario, 2002-2009. Can I Public Health Waken S, Hold Henningsen K, Kwong JC, Deck S L et al. On- time vaccination against whooping cough: comparison of hnese in preterm infants vaccinated against whooping cough: comparison of hnese different vaccines and effect of a booster dose. Vaccine.2013;11:1981-6 [70] Included (safety and immunogenicity) Lehkawa T, Tsaji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early measles vaccination (ALK-C strain) for preterm infants. Pediatr int.2013;55:163-8. Included (safety) intrunanogenicity) Included immunogenicity) 209. Ovaccination using survival analysis with a time-varying exposure. Ann Epidemiol.2012;02:22:799-806 Included Not pertinent english Wilson K, Hawken S. Incidence of advese veryes in premature children matching study on antibody response between preterm and full-term infants after primary lumuization of hepatits B vaccine. Zhonghua Liu King Bing Vue 2 Al: 2012;33:185-8. Not written in english Wilson K, Hawken S. Incidence of advese veryes in premature children				
vaccine against Streptococcus preumoniac in premature babies with low birth weight. Pediath Neonatol 2014 Apr;55(2):10:17 [65] (immunogenicity) Shen S, Campitelli MA, Calzavara A, Gutmann A, Kwong JC. Seasonal influenza vaccine effectiveness in pre- and full-term children aged 6-23 (effectiveness) Included (effectiveness) months over multiple seasons. Vaccine 2013;21:2974-8 [69] Kate 2014 Not pertinent Weison K, Hawken S, Holdt Henningsen K, Kwong JC. Deeks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can 1 Excluded Not pertinent Permeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccination (AIK-C strain) for preterm infants. Pediat Int 2013;55:163-8. Included (safety and immunogenicity) Included (safety and immunogenicity) Sposito S, Funagalli M, Principi N, Immunogenicity, aafety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;11:119- 209. Excluded Not pertinent Oblowing 2-month vaccination Linu Vaccin Immunopenicity, aafety and tolerability exposure. An Eigledmiol 2012;22:299-806. Included (safety) Oblowing 2-month vaccination Immunopenicity, aafety and tolerability of vaccination using arrival analysis with a time-varying exposure. An Eigledmiol 2012;22:299-96. Not written in english Wilson K, Hawken S, Incidence of adverse events in premature children following		x 1 1 1		
weight Pediatr Neonatol 2014 Apr;55(2):101-71(65) Included Shen S, Campitelli MA, Celzavara A, Guttmann A, Kwong JC, Seasonal Included (effectiveness) muthis over multiple seasons. Vaccine 2013;31:2974-8 (69) Included (effectiveness) Wilson K, Hawken S, Hold Henningsen K, Kwong JC, Deck S L et al. On- Excluded Not pertinent Public Health Waken S, Hold Henningsen K, Kwong JC, Deck S L et al. On- Included (immunogenicity) Persistence at one year of age of antigen-induced cellular immune responses included (safety immunogenicity) In related against whooping cough: comparison of hree (included (safety) immunogenicity) Included sign A, Taino M, Kusano R, Sugayama R et al. Effect of arry included (safety) and Included sign A, Taino M, Kusano R, Sugayama R et al. Effect of arry inmunogenicity) Excluded Review 209. Ahrens K, Lash TL, Louik C, Mitchell AA, Weler MM. Correcting for Excluded Not pertinent wilson K, Hawken S, Inciden using survival analysis with a funce-varying explish english wilson K, Hawken S, Inciden using survival analysis with a funce-varying explish english wilson K, Hawken S, Inciden using survival analysis with a func				
Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal Influenza vaccination effectiveness in pre-and full-term children agel 6-23 months over multiple seasons. Vaccine 2013;31:2974-8 [69] Included (effectiveness) Wilson K, Hawken S, Holdt Henningsen K, Kwong JC. Decks SL et al. On- time vaccination coverage in premature infants in Omario, 2002-2009. Can J Public Health 2012;10:2539-62 Included (effectiveness) Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, et al. preterm infants vaccinated against whooping cough: comparison of hircs different vaccines and effect of a booster dose. Vaccine 2013;31:1981-6 [70] Included (immunogenicity) Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of carly and that 2015;51:63-8. Included (safety and immunogenicity) Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolcrability of vaccinations in premature infants. Pediat exposure misclassification using survival analysis with a time-varying exposure. Am Epidemiol 2012; 22: 799-800. Not pertinent Oblowing 2-month vaccination Linu X-eck Immunother 2012; 58:59:25 [52] Included (safety) Included (safety) Ollowing 2-month vaccination. Hum Vaccin Immunother 2012; 58:59:52 [52] Not written in english atching study on antibody resporse between perterm and full-term infants after primary immunization of hepatits B vaccine: Zhonghua Liu Xing Bing Xue 2 2012(213):18:58. Not written in english weight infants. Product Kin D, 2012 Mar-Apr(2R);21:37-4 Not written in english english centesk1, 2012;62:32:37. Memus C, Schmaßsch G, Hatenstein S, Proquitté		(immunogenicity)		
influenza vaccine effectiveness in pre- and full-term children aged 6-23 (effectiveness) months over multiple seasors Vaccine 2013;31:2974-8169] (effectiveness) Wilson K, Hawken S, Holdt Henningen K, Kwong JC, Docks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can J Excluded Not pertinent Public Health 2012;10:2359-62 Includded Includded Includded Vermeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Includded Includded persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013;31:1981-61701 Includded (safety and immunogenicity) Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;14:1199- 209. Excluded Not pertinent Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure vacination. JHim Vaccin Immunother. 2012;8:592-5 [52] Included (safety) Tolkards JL, Zhai XJ, Li YP, Zhang W, Zhu PC, Huang T, et al. Multi-center matching study on antibody response belween preterm and full-term infants after primary immunization of hepatiffs P vaccine. Zhonghua Liu Xing Bing Xue 2 a Zhi 2012;33:188-8 Not written in english Meinus C, Schmaltsch G, Hunterstein S, Proquitté H, Roehr CC. Adverse eardiorespiratory events				
months over multiple seasons. Vaccinc. 2013;31:2974-81 (69) Not Wilson K, Hawken S, Holdt Henningsen K, Kwong JC, Decks SL et al. On I Excluded Not pertinent Public Health 2012;10:2539-62 Vermeuler F, Drits V, Verscheure V, Damis E, Vermeylen D, et al. Included Included Vermeuler F, Drits V, Verscheure V, Damis E, Vermeylen D, et al. Included Included Included Vermeuler F, Drits V, Verscheure V, Damis E, Vermeylen D, et al. Included (safety Included (safety Ichtwar T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early Included (safety Included (safety Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability Excluded Review 200. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for Excluded Not pertinent exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol 2012; 22:799-806 Included (safety) Following 2-month vaccination. JHim Vaccin Immunother. 2012; 3:52:51 [52] Included Not written in matchring study on antibody response between preterm and full-term infants english english witter primary Tummunization of Departitis B vaccine. Zhonghua Lit Xing Bing Not written in english		Included		
Wilson K, Hawken S, Holdt Herningsen K, Kwong JC, Deeks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can J Public Health 2012;10:e359-62 Not pertinent Vermeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Included Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccinated against whooping cough: comparison of three different vaccination (AIK-C strain) for preterm infants. Pediatr int 2013;55:163-8. Included Esposito S, Fumagalli M, Principi N, Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;14:1199- 209. Included Review Of vaccination cosin go and super-induced cellular immunogenicity insolution. JL Liv P, Zhong W, Zho KC, Unang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonglua Liu Xing Bing Xue 2 al: 213:123:18. Not written in english Weiradic CH, Liu RL, Lin R, Lin RL, Lin RL, Gentzen Lin Menucher 2012;43:194-6 (INU); 2013:18:54. Not written in english Meinus C, Schmalsofi G, Hatterstein S, Proquitté H, Roehr CC. Adverse eardioresprintary events following primary vaccination of very low birth weigh rinfants. J Pediater, Rice J, 2012;43:137-42. Not written in english Meinus C, Schmalsofi G, Hatterstein S, Proquitté H, Roehr CC. Adverse eardioresprintary events following primary vaccination of very low birth weigh rinfants. J Pediater, Rich J, 2012;47:47:137-42. Not written	influenza vaccine effectiveness in pre- and full-term children aged 6-23	(effectiveness)		
Wilson K, Hawken S, Holdt Herningsen K, Kwong JC, Deeks SL et al. On- time vaccination coverage in premature infants in Ontario, 2002-2009. Can J Public Health 2012;10:e359-62 Not pertinent Vermeulen F, Drix V, Verscheure V, Damis E, Vermeylen D, et al. Included Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccinated against whooping cough: comparison of three different vaccination (AIK-C strain) for preterm infants. Pediatr int 2013;55:163-8. Included Esposito S, Fumagalli M, Principi N, Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;14:1199- 209. Included Review Of vaccination cosin go and super-induced cellular immunogenicity insolution. JL Liv P, Zhong W, Zho KC, Unang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonglua Liu Xing Bing Xue 2 al: 213:123:18. Not written in english Weiradic CH, Liu RL, Lin R, Lin RL, Lin RL, Gentzen Lin Menucher 2012;43:194-6 (INU); 2013:18:54. Not written in english Meinus C, Schmalsofi G, Hatterstein S, Proquitté H, Roehr CC. Adverse eardioresprintary events following primary vaccination of very low birth weigh rinfants. J Pediater, Rice J, 2012;43:137-42. Not written in english Meinus C, Schmalsofi G, Hatterstein S, Proquitté H, Roehr CC. Adverse eardioresprintary events following primary vaccination of very low birth weigh rinfants. J Pediater, Rich J, 2012;47:47:137-42. Not written	months over multiple seasons. Vaccine.2013;31:2974-8 [69]			
time vascination coverage in premature infants in Ontario, 2002-2009. Can J Public Health.2012;10:e359-62 Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, et al. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vascinated against Moonging cough: comparison of three sponses immunogenicity) In preterm infants vascinated against Moonging cough: comparison of three sponses immunogenicity) Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of arly immunogenicity) Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol 2012; 22:7992606 Wilson K, Hawken S, Incidence of adverse events in premature children Included (safety) following 2-month vaccination. Hum Vaccin: Immunother: 2012; 3:592-5 [52] Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center after primary immunization of hepatits B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi:2012;33:185-8. Meinus C, Schmalisch G, Hantenstein S, Proquitté H, Rochr CC. Adverse cardiorespiratory events following primary vaccination of very low birth english weight rintaris. J Pediatar (Ni J). 2012 Mar-Apr;88(2):137-42 Gaudelle J, Labassine E, de Pontual L. Immunization of the preterm infants and english Lin TH, Lin SY, Lin CH, Lin HC et al. AdimFlus-S(®)		Excluded	Not pertinent	
Public Health.2012;10:e359-62 Included Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, et al. Included Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vascinated against whooping couple, comparison of three different vascines and effect of a booster does. Vaccine.2013;31:1981-67[0] Included (safety and immunogenicity) Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early measles vascination (AIK-C strain) for preterm infants. Pediat intro13;55:163-8. Included (safety and immunogenicity) Esposito S, Furnagalli M, Principi N. Immunogenicity, safety and tolerability of vascinations in premature infants. Expert Rev Vascines.2012;1:1199- 209. Excluded Not pertinent Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol 2012; 22:799:806 Included (safety) Following 2-month vascination. Hum Vascin Immunother.2012; 8:592-51521 Not written in english Not written in english Meinus C, Schmafisch G, Hatenstein S, Proquitté H, Rochr CC. Adverse eardiorespiratory events following primary vascination of very low birth weight rifinati. Pediatr (Mi 0): 2012 Mar-Apr;88(2):175-42 Not written in english Gaudellis J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Brat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SP, ULin CH, Lin RL Lin HC et al. AdimFlu-S(®) influenza A (H1N1)			····I·····	
Vermeulen F, Dirix V, Verscheure V, Damis E, Vermeylen D, et al. Included Persistence at one year of age of antigen-induced cellular immune responses (immunogenicity) in preterm infants vaccinated against Mooping cough: comparison of three sponses (immunogenicity) Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early Included (safety measles vaccination (AIK-C strain) for preterm infants. Pediati and int.2013;55:163-8. immunogenicity) Esposito S, Rumagalli M, Principi N. Immunogenicity, safety and telefability Excluded of vaccinations in premature infants. Expert Rev Vaccines:2012;11:1199-209. Not pertinent 20.9. Mirens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for Excluded Not pertinent exposure. Ann Epidemiol.2012;22:799-806 Included (safety) Included (safety) following 2-month vaccination. Hum Vaccin Immunother: 2012;8:592-5 [52] Included (safety) english weight rintari. SJ, Li YP, Atang W, Zhu FC, Huang T, et al. Multi-center Excluded Not written in eradiorespiratory events following primary vaccination of very low birth english english weight rintari. S. Pediat (Kio J). 2012 Mar-Apr;80(2):137-42 Excluded Not written in Gaudelis J, Tachassime E, de Pontual L. Immuniz				
Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine 2013;31:1981-6[70] Included (safety and immunogenicity) Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early measles vaccination (AIK-C strain) for preterm infants. Pediatr int 2013;55:163-8. Included (safety immunogenicity) Esposito S, Furnagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;11:1199- 209. Excluded Review Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol.2012; 22:799-806 Included (safety) following 2-month vaccination. Hum Vaccint Immunother.2012;8:592-5 [52] Included (safety) following 2-month vaccination. Hum Vaccint Immunother.2012;8:592-5 [52] Excluded Not written in english Mitins C, Schmafisch G, Hatenstein S, Proquitté H, Rochr CC. Adverse cardiorespiratory avents following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;58(2):137-42 Excluded Not written in english Gaudelus J, Lachassime E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RL Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaceine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine 2012;156:A13797. <t< td=""><td></td><td>Included</td><td></td><td></td></t<>		Included		
in preterm infants vaccination digits whooping cough: comparison of hiree different vaccines and effect of a booster dose. Vaccine, 2013;31:1981-6[70] Lehikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early measles vaccination (AIK-C strain) for preterm infants. Pediatr Int.2013;55:163-8. Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines, 2012;11:1199- 209. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure minoclassification using survival analysis with a time-varying exposure. Ann Epidemiol.2012; 22:799-806 Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother: 2012;8:592-5 [52] Chang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Meinus C, Schmaftsch G, Hatterstein S, Proquitté H, Rochr CC. Adverse eardioresprisory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Gaudelis J, Tachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;02:328-3 Lin TH, Lin SY, Lin CH, Lin RL, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Buijs SC, Boersma B. Cardiorespriratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd 2012;156:A3797. Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized pha				
different vaccines and effect of a booster dose. Vaccine 2013;31:1981-6 (70) Included (safety lchikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early Included (safety measles vaccination (AIK-CS train) for preterm infants. Pediatr Included (safety gand immunogenicity) Esposito S, Furnagalli M, Principi N. Immunogenicity, safety and tolerability Excluded Review of vaccinations in premature infants. Expert Rev Vaccines 2012;11:199-209. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for Excluded Not pertinent exposure misclassification using survival analysis with a time-varying exposure insiclassification using survival analysis with a time-varying Excluded Not pertinent exposure. Ann Epidemiol 2012; 22: 799-806 Included (safety) Following 2-month vaccin timmunother 2012; 8:592-5 [52] Included (safety) following 2-month vaccination. Hum Vaccin Immunother 2012; 8:592-5 [52] Included Not written in matching study on antibody response between preterm and full-term infants english english Xue Za Zhi 2012;33:185-8 Keries Not written in english Kater Junay immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Keries Not written in gaude fus J Lachassinne E, de Pontual L. Immunization of thep tet		(minunogenicity)		
Ichikawa T, Tsuji A, Fujino M, Kusano R, Sugiyama R et al. Effect of early measles vaccination (AIK-C strain) for preterm infants. Pediatr Int.2013;55:163-8. Included (safety and immunogenicity) Esposito S, Fumagalli M, Principi N, Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;11:1199- 209. Excluded Review Ahrens K, Lash TL, Louik C, Mitchell AA, Wepler MM, Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol.2012;22:799-806 Included (safety) Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Excluded Not written in english Gaudelus J, Lachaixsti G, Hattenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low bitth weight mfants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Lin TH, Lin SY, Lin HC et al. AdimFlu-S(@) influenza A (H1TH) vacgine during pregnancy: the Taiwanese Pharmacovigilance Survey. Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, C et J, Sterster Aler First immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneestd.2012;156:A3797. Included (safety and immunogenicity)				
measles vaccination (AİK-C strain) for preterm infants. Pediatr and immunogenicity Lnt.2013;55:163-8. immunogenicity Excluded Review Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability Excluded Review 209. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for Excluded Not pertinent exposure misclassification using survival analysis with a time-varying Excluded Not pertinent exposure. Ann Epidemiol 2012;22:799-806 Included (safety) following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Zhang L, Zhai XJ, Li YP, Zhang W, Zhi FC, Huang T, et al. Multi-center Excluded Not written in matching study on antibody response between preterm and full-term infants english english Weinus C, Schmalisch G, Hattenstein S, Proquitté H, Roehr CC. Adverse Excluded Not written in cardiorespiratory events following primary vaccination of very low birth english english Weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Guadelus J, Lachassinne E, de Pontual L. Immunization of the preterm Excluded Not written in infant, Rev Prat.2012;62:382-3 Lim TH, Lim RY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A Excluded Not pertinent H1N1V) accine during pregnacy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012;Mar:30;30(16):2671-5. Suster				
Int.2013;55:163-8. immunogenicity Esposito S, Furnagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines 2012;11:1199- 209. Excluded Review Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol 2012;22:799-806 Excluded Not pertinent Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2012;33:185.8. Not written in english Meinus C, Schmafisch G, Hattenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3 Excluded Not pertinent Uhr TH, Liu SY, Lin CH, Lin RL Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vacque during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Not pertinent Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in preterm European Infants: a prospe				
Esposito S, Fumagalli M, Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines. 2012; H: 1199- 209. Excluded Review Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure. Ann Epidemiol. 2012; 22: 799-806 Excluded Not pertinent Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother. 2012;8:592-5 [52] Included (safety) Zhang L, Zhan XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2012;35:185-8. Not written in english Meinus C, Schmalisch G, Hattenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RL in HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwances Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93 Included (safety and immunogenicity) Turn H, Lin SY, Lin CH, Lin KH, Kinshimaki S, et al. Immune respo				
of vaccinations in premature infants. Expert Rev Vaccines 2012;11:199-209.		immunogenicity)		
209. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol. 2012; 22:799-806 Excluded Not pertinent Wilson K, Hawken S. Incidence of adverse events in premature children matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghu, Zhui XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center Excluded Not written in english Meinus C, Schmaftsch G, Hartenstein S, Proquitté H, Rochr CC. Adverse cardiorespiratory events following primary vaccination of very low birth Excluded Not written in english Gaudelus J, Lachassinen E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:38-3. Internet Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Excluded Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Excluded Not written in english Guides J, 1487-93 Included (safety and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis immunogenicity) Included (safety and immunogenicity of the human rotavirus vaccine in preterm and immunogenicity of the human rotavirus vaccine in preterm and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIB		Excluded	Review	
Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. Ann Epidemiol.2012;22:799-806 Not pertinent Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Not written in english Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Rochr CC. Adverse eardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Excluded Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797. Included (safety and immunogenicity) Included (safety and immunogenicity) Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47] Included (safety	of vaccinations in premature infants. Expert Rev Vaccines.2012;11:1199-			
exposure misclassification using survival analysis with a time-varying immunosity exposure. Ann Epidemiol.2012;22:799-806 Included (safety) Wilson K, Hawken S. Incidence of adverse events in premature children Included (safety) following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center Excluded Not written in matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Meinus C, Schmalisch G, Hattenstein S, Proquitté H, Roehr CC. Adverse Excluded Not written in cardiorespiratory events following primary vaccination of very low birth english weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm Excluded Not written in infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A Excluded Not written in Infants. 2 prospective cohort study]. Ned Tijdschr geneskd.2012;156:A3797. Guedued (safety Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryaki	209.			
exposure misclassification using survival analysis with a time-varying immunosity exposure. Ann Epidemiol.2012;22:799-806 Included (safety) Wilson K, Hawken S. Incidence of adverse events in premature children Included (safety) following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center Excluded Not written in matching study on antibody response between preterm and full-term infants after primary immunization of hepatitits B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Meinus C, Schmalisch G, Hattenstein S, Proquitté H, Roehr CC. Adverse Excluded Not written in cardiorespiratory events following primary vaccination of very low birth english weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm Excluded Not written in infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A Excluded Not written in Infants. 2 prospective cohort study]. Ned Tijdschr geneskd.2012;156:A3797. Gomenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Included (safety </td <td>Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for</td> <td>Excluded</td> <td>Not pertinent</td> <td></td>	Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for	Excluded	Not pertinent	
exposure. Ann Epidemiol.2012;22:799-806 Included (safety) Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-cerner matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8. Excluded Not written in english Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Excluded Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797. Excluded Not written in english Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Included (safety and immunogenicity of the human rotavirus vaccine in preterm and immunogenicity) Included (safety and immunogenicity of the human rotavirus vaccine in immunogenicity) J.2012;31:487-93 Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenze type b conjugate vaccine in preterm and immunogenicity) Inclu			1	
Wilson K, Hawken S. Incidence of adverse events in premature children following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52] Included (safety) Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2012;33:185-8. Excluded Not written in english Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42 Excluded Not written in english Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3 Excluded Not written in english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5. Excluded Not written in english Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797. Included (safety and immunogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93 Included (safety and immunogenicity) Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediar Int. 2012;54:64-7 [47] Included (safety and immunogenicity) <td></td> <td></td> <td></td> <td></td>				
following 2-month vaccination. Hum Vaccin Immunother.2012;8:592-5 [52]Zhang L, Zhai XJ, Li YP, Zhang W. Zhu FC, Huang T, et al. Multi-center matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8.Not written in englishMeinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42ExcludedNot written in englishGaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot written in englishBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.Included (safety and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included isafety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerKxuededNot pertinent		Included (safety)		
Zhang L, Zhai XJ, Li YP, Zhang W, Zhu FC, Huang T, et al. Multi-center Excluded Not written in matching study on antibody response between preterm and full-term infants Excluded Not written in after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Not written in english Weinus C, Schmafisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse Excluded Not written in cardiorespiratory events following primary vaccination of very low birth english english Weinus C, Schmafisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse Excluded Not written in cardiorespiratory events following primary vaccination of very low birth english english Gaudefus J, Lachassinne E, de Pontual L. Immunization of the preterm Excluded Not written in infant. Rev Prat.2012;62:382-3 english english Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A Excluded Not pertinent (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vacine.2012 Mar 30;30(16):2671-5. Not written in Buijs SC, Boersma B. Cardiorespiratory events after first immunization in Excluded Not written in geneeskd.2012;156:A3797. Included (safety and Safety, reactogenicity and		mended (surery)		
matching study on antibody response between preterm and full-term infants after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8.englishMeinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42ExcludedNot written in englishGaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot written in englishBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.Included (safety and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerKudedNot pertinent		Englished	Natarmittan in	
after primary immunization of hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi.2012;33:185-8		Excluded		
Xue Za Zhi.2012;33:185-8.Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42ExcludedNot written in englishGaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot written in englishBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.Included (safety and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerKezcludedNot pertinent			english	
Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42ExcludedNot written in englishGaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerKxcludedNot pertinent				
cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42englishGaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent				
weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42Gaudelus J, Lachassinne E, de Pontual L. Immunization of the preterm infant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		Excluded	Not written in	
Gaudelus J, Lachassinne E, de Pontual L. Immunization of the pretermExcludedNot written in englishInfant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent	cardiorespiratory events following primary vaccination of very low birth		english	
Gaudelus J, Lachassinne E, de Pontual L. Immunization of the pretermExcludedNot written in englishInfant. Rev Prat.2012;62:382-3ExcludedNot written in englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent	weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137-42			
infant. Rev Prat.2012;62:382-3englishLin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerK. KudedNot pertinent		Excluded	Not written in	
Lin TH, Lin SY, Lin CH, Lin RI, Lin HC et al. AdimFlu-S(®) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.ExcludedNot pertinentBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		· · · · · · · · · · ·		
(H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. Vaccine.2012 Mar 30;30(16):2671-5.Not written in englishBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		Excluded		
Vaccine.2012 Mar 30;30(16):2671-5.ExcludedBuijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		LACIUUCU	Not pertinent	
Buijs SC, Boersma B. Cardiorespiratory events after first immunization in premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.ExcludedNot written in englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent				
premature infants: a prospective cohort study]. Ned Tijdschr Geneeskd.2012;156:A3797.englishOmenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		E- 1 1 1	N-4	
Geneeskd.2012;156:A3797.Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent		Excluded		
Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, et al.Included (safety and immunogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93Included (safety and immunogenicity)Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent			english	
Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J.2012;31:487-93and immunogenicityTsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47]Included (safety and immunogenicity)Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lowerExcludedNot pertinent				
preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis immunogenicity) J.2012;31:487-93 immunogenicity) Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune Included (safety response to Haemophilus influenzae type b conjugate vaccine in preterm and infants. Pediatr Int. 2012;54:64-7 [47] immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded		Included (safety		
J.2012;31:487-93 Included (safety Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune Included (safety response to Haemophilus influenzae type b conjugate vaccine in preterm and infants. Pediatr Int. 2012;54:64-7 [47] immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded	Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in			
J.2012;31:487-93 Included (safety Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune Included (safety response to Haemophilus influenzae type b conjugate vaccine in preterm and infants. Pediatr Int. 2012;54:64-7 [47] immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded	preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis	immunogenicity)		
Tsuda K, Iwasaki S, Horiguchi H, Mori M, Nishimaki S, et al. Immune Included (safety response to Haemophilus influenzae type b conjugate vaccine in preterm and infants. Pediatr Int. 2012;54:64-7 [47] immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded Not pertinent				
response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64-7 [47] and immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded Not pertinent		Included (safetv		
infants. Pediatr Int. 2012;54:64-7 [47] immunogenicity) Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded				
Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F et al. Wheezing lower Excluded Not pertinent				
respiratory disease and vaccination of premature infants.	Mullooly IP Schuler R Mesa I Draw I DeStefano F at al Wheaving lower	• •/	Not pertinent	
	respiratory disease and vaccination of promature infante	LACIUUCU	Not pertilient	
	respiratory disease and vaccillation of premature infants.			

Vaccine.2011;29:7611-7			
Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J et al.	Included (safety		
Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup	and		
C vaccine is immunogenic and well tolerated in preterm infants when	immunogenicity)		
coadministered with other routinely recommended vaccines. Pediatr Infect			
Dis J.2011;30:e216-24 [53]			
Omeñaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V,	Included (safety		
Kafetzis D. Immunization of preterm infants with 10-valent pneumococcal	and		
conjugate vaccine. Pediatrics 2011;128:e290-8 [54]	immunogenicity)		
Calderón C G, Moore V R, Pittaluga P E, Potin S M. Adherence to	Excluded	Not written in	
immunizations in newborns less than 1500 gr at birth and/or younger than 32		english	
weeks, in two chilean centers. Rev Chilena Infectol.2011;28:166-73			
Clifford V, Crawford NW, Royle J, Lazzaro T, Danchin M, et al. Recurrent	Included (safety)		
apnoea post immunisation: Informing re-immunisation policy. Vaccine.2011;29:5681-7. [33]			X
Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A et al. Influenza	Included (safety		
A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23	and	•	
months. Pediatrics.2011 May;127:e1161-8. [48]	immunogenicity)		
Zanoni G, Gottin L, Boner A, Piacentini G, Peroni D et al. Case discussion of	Excluded	Case report	
an immediate serious reaction to hexavalent vaccine mistaken for			
anaphylaxis. Br J Clin Pharmacol.2010;70:916-7.			
Mirpuri J, Jain L. Issues of prematurity and HIV infection. Clin	Excluded	Not pertinent	
Perinatol.2010;37:887-905			
Baxter D. Premature infants and vaccination. Hum Vaccin.2010;6:493.	Excluded	Comment on	
Trück J, Pollard AJ. Challenges in immunisation against bacterial infection in	Excluded	Not pertinent	
children. Early Hum Dev.2010;86:695-701.		riot pertinient	
Dhillon S. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). BioDrugs.2010;24:299-302	Excluded	Review	
	Enclosed	Denien	
Baxter D. Vaccine responsiveness in premature infants. Hum Vaccin.2010;6:506-11	Excluded	Review	
Baxter D. Impaired functioning of immune defenses to infection in premature	Excluded	Review	
and term infants and their implications for vaccination. Hum			
Vaccin.2010;6:494-505.			
Tinnion RJ, Berrington JE. Flu vaccination for ex-preterms and infants under	Excluded	Letter	
6 monthsare we getting it right? Arch Dis Child.2010 May;95:400-1			
Baxter D, Ghebrehewet S, Welfare W, Ding DC. Vaccinating premature	Included		
infants in a Special Care Baby Unit in the UK: results of a prospective, non-	(immunogenicity)		
inferiority based, pragmatic case series study. Hum Vaccin.2010;6:512-20.			
Pinquier D, Adde-Michela C, Ploin D, Levêque C, Marret S; Vaccination rate	Excluded	Not written in	
of premature infants at 6 and 24 months of age: a pilot study. Arch		english	
Pediatr.2009 Dec;16:1533-9.			
Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vaccines and preterm	Excluded	Review	
neonates: why, when, and with what. Early Hum Dev 2009;85:S43-5.			
Fleischer L, Syed SS. Hepatitis B surface antigenemia in a neonate following	Excluded	Case report	
vaccination with Pediarix. Clin Pediatr.2009;4:311-2.		Ĩ	
Ryan MA, Gumbs GR, Conlin AM, Sevick CJ, Jacobson IG et al. Evaluation	Excluded	Not pertinent	
of preterm births and birth defects in liveborn infants of US military women		1	
who received smallpox vaccine. Birth Defects Res A Clin Mol			
Teratol.2008;82:533-9			
Klein NP, Massolo ML, Greene J, Dekker CL, Black S et al. Risk factors for	Included (safety)		
developing apnea after immunization in the neonatal intensive care unit.	(Surery)		
Pediatrics.2008;121:463-9 [60]			
T = 11 - 2 - 0.025 + 121.403 - 9 [00]			

Table 2: Sixty-one articles identified with the search details (infant, preterm"[MeSH Terms]) AND "vaccination"[MeSH terms] and exclusion criteria for the screening relying on studies' abstracts or titles.

Author (year)	Design	No of pts	Gestatio nal Age in weeks (w)	Location	Vaccine	Objectives	Follow up (FU) after vaccine	Results	Bias
Ben Jmaa et al. (2017) 62	Prospective randomized, double blinded, placebo- controlled	56	< 32 w	Canada	DTPa,IPV, Hib, PCV10	To analyze cardio- respiratory Events (CREs) 48 hours after vaccination and inflammatory eesponse after primary Immunization	48 h	-Significant correlation between Δ C- reactive protein and Δ Total CRE/patient/24 hours; -CRE/patient/24 hours was unchanged before versus after immunization (6.7 ± 7.7 before versus 6.8 ± 9.7 after, P = 0.9) in the ibuprofen group	

Kjærgaard	Prospective	4262	32-37 w	Denmark	BCG	Effects of BCG	22	There was no effect of BCG on	
et al. (2016) 43	randomized, multicenter clinical trial	(144 born 32-37 w)	32-37 W	Denmark	bed	vaccination on early childhood infections, growth and development in term and preterm infant	months	either incidence of infections, growth, body composition or psychomotor development	
Kjærgaard et al. (2016) 44	Prospective randomized, multicenter clinical trial	4262 (144 born 32-37 w)	32-37 w	Denmark	BCG	To assess the non-specific effect of Bacillus Calmette-Guérin (BCG) vaccination at birth on psychomotor development	22 months	Lack of a Negative Effect of BCG- Vaccination on Child Psychomotor Development	
Kent et al (2016) 49	Phase IV, open-label, prospective, multicenter, randomized controlled trial	199	<35 w	UK	PCV13 in association with other polyvalent vaccines	To evaluate solicited adverse events (AEs)	28 days	 no significant differences in the frequency or severity of local and systemic AEs between vaccination schedules at any time point 77 serious AEs, of which 1 possibly related to vaccination unexpected serious adverse reaction from each randomized group 	
Wilińska et al (2016) 55	Observational prospective	138	$73 \le 28$ w 65 > 28 w	Poland	DTPa-IPV- HBV-Hib- PCV	To assess incidence of adverse events following vaccination (AEFV) monitoring cardio- respiratory functions and body temperature	72 hours	- Apnea and activity dysfunctions were the relatively most frequent AEFI. -Preterm newborns who experienced apnea show significantly more frequent late onset sepsis (p=0.028) as well as a history of longer use of continuous positive air pressure (CPAP) (p=0.033)	-no control group -small sample size
De Meo et al (2015) 58	Multicenter retrospective cohort study	13,926	≤28 w	USA	DTPa, IPV, HBV, Hib, PCV7	To assess sepsis evaluation (collection of blood culture), need of increased respiratory support, seizures and death in the 3 days following vaccination	3 days	The incidence of sepsis evaluation and increased respiratory support increase from the pre-immunization period to the post-immunization period -Infants 23–24 weeks of gestation demonstrated an increased incidence of sepsis evaluation and increased respiratory support compared to older infants (27– 28 weeks gestation) -A prior history of gram-positive sepsis was associated with an increased rate for sepsis evaluation in the post-immunization period. -There was no difference in the incidence of adverse events in combination vaccines versus single- dose vaccines.	-"healthy vaccinated "effect -physicians may be more likely to document adverse events that are occurring in close proximity to the administrat ion of immunizati ons
McCrossan et al (2015) ⁵¹	Retrospective	344	<37 w	Ireland	DTPa, IPV, HBV, PCV, Hib	To assess delay in administration and safety of vaccines in preterm		None of the patients had a documented adverse reaction	- Retrospecti ve study -not clear the period of follow up
Saroha et al (2015) 42	Prospective randomized comparative trial	117	31-33 w	India	BCG	To compare complications of BCG vaccine in preterm infants aged 31–33 weeks immunized at birth or at 34 completed weeks	6 months	-Left axillary lymphadenopathy was the only complication seen in 3.4% of patients in in both groups -BCG vaccine may be safely given to moderately preterm infants (31–33 weeks) at birth	
Roué et al (2014) 45	Population- based study	7150	6883>37 w 267<37 w	France	Rotavirus vaccine	To analyze the cause of hospitalizations for up to 42 days after the last dose of Rotavirus vaccine	42 days	-No significant differences in severe AEs following vaccination between premature and term infants were found (5.2% versus 8.1%, $p = 0.09$). -No case of intussusception nor of Kawasaki disease were reported.	
Ichikawa et al (2013) 41	Prospective	17	<34 w	Japan	Measles vaccine	To evaluate immunogenicity and safety of early vaccination with measles vaccine at 6 months.	12 months after birth	AEs did not occur	Small sample
Anderson et al (2012) 56	Retrospective	203	≤28 w	Australia	DTaP, IPV, Hib, PCV	To evaluate likely/possible apneic reaction within 48 hours following 2 months vaccination	48 h	-18 preterm infants had a vaccine reaction, 17 with likely/possible apnea reaction (incidence 8,4%) after 2 months vaccination -Babies reacting to the 2-month vaccine were statistically of lower birth gestation and birth weight - There were no reactions to the following vaccine doses	-Small case numbers -lack of cardiorespi ratory monitoring for the 4- month immunizati ons in approximat ely 50% of

									cases
Omenaca et al (2012) 46	randomized double blinded placebo- controlled trial	250	≥27 and <37 w	France, Portugal, Poland, Spain	Rotavirus vaccine	To assess the occurrence of any solicited and unsolicited AEs during the 15- and 31-day postvaccination follow-up period after each dose, respectively and severe adverse event (SAE)	31 days	 Frequency of AEs recorded in the vaccine and placebo groups were similar (P = 0.266). During the 31-day postvaccination follow-up period, at least 1 unsolicited AE was reported in 196 (29.3%, 95% CI: 25.8–32.9%) and 138 (40.7%, 95% CI: 35.4–46.1%) infants in the vaccine and placebo groups, respectively (P < 0.05). The percentage of all and grade 3 solicited general AEs recorded during the 15-day postvaccination follow-up period were similar in both groups (P > 0.05) with irritability being the most common AE reported 	- coadminist ration of other polyvalent vaccines
Tsuda et al (2012) 47	prospective cohort study	54 preterm infants	<37 w	Japan	Hib	To assess immunogenicity and side-effects after vaccination		-Side-effects after vaccination were rare, with only one case of local redness	-small number of samples -not clear the follow up period
Wilson et al (2012) 52	Retrospective self- controlled case-series	771453	-49220 born 33- 36 w -7392 born ≤ 32 w	Canada	DTPa-IPV- HiB-PCV	-to evaluate rates of emergency room visits and hospital admissions within 3 days following 2 months vaccination	3 days	-Reduced AEs (as emergency room visits and hospital admission) were observed in preterm infants when compared to small for gestational age term children. When compared with all term children this decrease in risk was not statistically significant.	-the healthy vaccine effect - emergency room visits and hospital admissions within 3 days following vaccination could not be related to vaccination
Clifford V et al (2011) ³⁴	Observational retrospective	46	-38 born < 37 w -8 born ≥37 w	Australia	DTPa-IPV- HBV- HiB+PCV7 and rotavirus vaccine	-To determine recurrence rates for AEs following 2 or 4 month immunisations over 48 hours after vaccination. -To explore potential risk factors for recurrence of apnea	48 hours	 -35/38 preterm infants had an apnoea following their 2-month vaccine, 3/38 had an apnea after their 4-month vaccine -7/38 (18%) preterm infants had recurrent apnoea -Lower birth weight (p = 0.04) and ongoing hospitalisation for complications relating to prematurity (p = 0.01) increased the odds of a recurrent apnoea AEFI. No infant with recurrent apnoea at 4-months suffered a third apnoea AEFI at their 6-month immunisations 	-small sample size - overestima tion of the number of infants with a first apnoea AEFI maybe because of the retrospecti ve nature of the study without the possibility to confirm the apnoea diagnosis
Esposito et al. (2011) ⁴⁸	Prospective, randomized open trial	101	-34 born <32 w -35 born 32-36 w -32 born ≥37 w	Italy	Influenza A/H1N1 MF59- adjuvanted vaccine	To assess immunogenicity, safety and tolerability of influenza A/H1N1 MF59- adjuvanted vaccine in preterm and term children aged 6 to 23 months	14 days	-The incidence of local AEs was 2,9- 3,1% in all children -The only systemic AE consistently recorded was fever, more frequently after the first dose than after the second dose in all the groups(P<0.05) -None of the enrolled children experienced any severe AE.	
Omeñaca et al (2011) 53	open, controlled prospective multicenter study	313	-56 born <31w -107 born 31- 36 w -150 full term	Spain	Hib-MenC- TT	To assess immunogenicity and safety profile in preterm infants compared with full-term born infants. To record specific local and general solicited adverse events for 4 days after each vaccination and	31 days	-solicited local symptoms tended to be lower than those observed after DTPa-HBV-IPV-PCV7 -Grade 3 local symptoms were reported by no more than 7.6% -No evidence of increasing reactogenicity with an increasing number of doses in any group. -Grade 3 general symptoms were	-open design -no randomizat ion

						to record unsolicited adverse events for 31 days after vaccination		reported by no more than 9.3% and 2.8% of patients after primary vaccination and after the booster dose respectively	
Omeñaca et al(2011) 54	Prospective clinical trial	286	-50 born 27-30 w -87 born 31-36 w -149 full term	Spain, Greece	PHID-CV	To evaluate immunogenicity and safety to PHiD-CV and coadministered vaccine at 2-4-6 month of age, followed by a booster dose at 16-18 months of age. To evaluate local and general adverse events for 4 days after each vaccine dose and unsolicited adverse events for 31 days after vaccine and serious adverse events for 6 months after booster vaccination.	6 months	-The most frequently reported solicited general AE were irritability, drowsiness, fever and loss of appetite, but the incidence of high grade of general AE was low (i.e. 0,8-1,5% incidence of fever > 39°C within 4 days after each of the vaccine dose, 7.1% after the booster dose) -Incidence of grade 3 solicited local AEs was low in both groups, but higher after booster vaccination in the term groupSAEs were reported but no one were considered as causally related to vaccination - One episode of apnea was reported in a preterm infant after the first primary dose but was not considered to be related to study vaccination and resolved without sequelae.	
Furck et al (2010) 57	prospective observational trial	473	<37 w	Germany	DTPa, Hib, HBV, IPV, PCV7	To assess AEs for up to 48h following vaccination	48 hours	-The frequency of side effects was 10.8% and 2.8 % for appear/bradycardia and local reaction/fever respectively The chance of suffering from appea decreased with increasing gestational week at birth -Fever was significantly more frequent in infants with cerebral hemorrhage grade 3–4 or with periventricular leukomalacia (OR 8,7 and 8,2 respectively)	-The 3 groups did not have the same number of infants -the gestational age as the time of vaccination decreased over the years
Hacking et al. (2010) 59	Retrospective historical cohort study	411	27 w	Australia	DTPa, Hib, HBV, OPV/IPV, PCV7	To evaluate initiation of respiratory support (CPAP) or intermittent positive pressure ventilation (IPPV) within 7 days of the 2-month scheduled vaccination	7 days	-22 preterm infants experienced some respiratory deterioration in the first 3 day after vaccination attributed solely to the immunization -infants requiring respiratory support following vaccination had a higher incidence of previous septicaemia (p = 0.02) and had a greater mean total accumulated time on CPAP prior to receiving immunizations (p=0.03)	- retrospecti ve nature of the study cannot suggest that immunizati on was a causative factor
Klein et al (2010) 50	open-label prospective study, self- controlled case series approach	83	-33 born <37w -50 born≥37 w	USA	DTPa, Hib, HBV, IPV, PCV	to describe potential vaccine-related AEs during the 30 days after each of 3 doses comparing the frequency of these events in preterm and term infants	30 days	-No AEs like fever, seizure, or swelling were reported for either preterm or term infants -Self-controlled case series analyses showed no increase in AEs among preterm and term infants after any vaccine dose	Small sample size
Carbone et al. (2008) 61	Randomized, controlled, blinded multicenter study	197	< 37 w	USA	DTPa	To evaluate increase in cardiorespiratory events after DTPa in preterm infants	48 hours	Absence of increase in cardiorespiratory events in DTaP group versus the control group	no long- term observatio n of the untreated control group.
Flatz- Jequier et al (2008) 35 Klein et al.	Retrospective	64	<32 w 456 born	Switzerlan d USA	DTPa- IPV/HIB/- PCV/anti VRS DTPa-IPV-	To evaluate occurrence of cardiorespiratory events after first DTPw or DTPa immunization in VLBW during the first 48 hours after second dose of vaccine	48 hours 48 hours	 -33/64 showed significant cardiorespiratory event after the 2 months vaccine. -6/33 require medical intervention (i.e. oxygen supplementation through nasal cannula in 4 patients, tactile stimulation in 1 patients, mask ventilation in 1 patients, mask ventilation in 1 patients, after the 4 months vaccine -None showed significant cardiorespiratory event after the third vaccine -A previous AE to vaccine was a risk factors for recurrence of cardiorespiratory events. - 95% episodes of postimmunization 	- retrospecti ve study
(2008) 60	study	177	430 00111 ≤30 w	00/1	HBV-Hib-	associated with	10 110015	apnea (62 of 65 episodes) occurred	

		PCV	postimmunization apnea	among infants born at ≤31 weeks of	
	41 born			gestation	
	31-41 w			-Bivariate analysis revealed that	
				postimmunization apnea was	
				markedly associated with the	
				presence of preimmunization apnea	
				(P < 0.0001)	
				- Multivariate analysis conducted	
				exclusively among infants without	
				apnea before immunization similarly	
				found that SNAP-II >10 (AOR: 4.2;	
				95% CI: 1.2-14.3), chronological	
				age of <67 days (AOR: 2.3; 95% CI:	
				1.1-4.8) and weight of <2 kg (AOR:	
				2.1; 95% CI: 1-4.5) were associated	
				with postimmunization apnea.	

Table 3. Studies regarding vaccine safety in preterm infants [Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H.influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II); AOR=adjusted odd ratio; CI=confidence interval].

Study (year)	Design	No of pts	Gestational Age in weeks (w)	Location	Vaccination	Objectives	Results	Bias
Ferreira et al. (2018) 64	Prospective study	121 -65 preterm infants -56 full-term infants	25-34.4 w	Brazil	MMR	to compare the immune response to measles and varicella vaccination in infants born prematurely with those born at full-term measuring measles antibodies at 12 and 15 months (before and after MMR vaccine) and varicella antibodies at 15 and 18 months (before and after vaccine)	 The percentages of infants with humoral immunity to measles and varicella after vaccination were similar in both groups antenatal corticosteroid use reduced the level of measles antibodies (p = 0.009), while breastfeeding for more than six months increased antibody levels after varicella vaccination (p = 0.023). 	
Martinón- Torres et al. (2017) 67	open-label, 2- arm, multicenter, parallel-group study	200 -100 full term infants -100 preterm infants	-25 born <29 w -50 born 29–31 w -25 born 32–36 w	Spain and Poland	PCV13	To evaluate antipneumococcal antibody responses elicited by PCV13 1 and 2 years after the fourth dose (toddler dose) in formerly preterm infants compared with term infants	-IgG GMCs in both infant groups at the 1-year and 2-year follow-up visits were lower than GMCs 1 month after the toddler dose for all serotypes. -Compared with term infants, IgG GMCs in preterm infants were statistically significantly lower at both follow-up time points for serotypes 6B, 18C, 19A, 19F and 23F; IgG GMCs for serotypes 5, 6A and 9V were statistically significantly lower in preterm infants at the 1-year follow-up only	
Kent et al. (2016) 49	Open label, randomized, controlled multicenter clinical trial	199	<35 w	UK	PCV13 -group 1: reduced schedule (vaccine at 2 and 4 months of age) -group 2 accelerated schedule (vaccine at 2, 3,	To assess the immunogenicity of 3 commonly used PCV13 priming schedules in premature infants and their response to a 12-month booster dose.	-Lack of seroprotection for more than one-half of the PCV13 serotypes was seen in 25%, 12%, and 3% of participants receiving the reduced, accelerated, and extended schedules, respectively ($P < 0.001$). -A reduced priming schedule of PCV13 resulted in higher post- booster IgG concentrations but lower post-primary	

					and 4 months of age)		concentrations. -Later gestation was associated		
					-group 3 extended schedule (vaccine at 2, 4,		with an increase in post-primary vaccination IgG concentrations for some serotypes, while receipt of antenatal steroids was		
					and 6 months of age)		associated with decreased odds of seroprotection at 2 months and after primary immunization for some serotypes.		
Saroha et al. (2015) 42	Prospective randomized comparative trial	117 -69 received BCG at birth (group 1) -48 received BCG at 34 w(group 2)	31-33 w	India	BCG	To evaluate immunogenicity of early vs delayed BCG vaccination in moderately preterm (31-33 weeks) infants.	-the rise of IFN-g levels measured 6 months after BCG in 2 groups was comparable ($p > 0.05$) -In group 1, 39.1% infants had positive Mantoux reaction (5–9 mm) 6 months after BCG whereas 37.5% infants in group 2 had positive Mantoux test ($p = 0.473$) -Six infants (5.12%) failed to develop BCG scar - the overall immunogenicity of BCG was 98.3%	A	
van den Berg (2015) 66	Prospective randomized trial	113 divided into 2 groups: -1 group received enteral oligosaccharides mixture during days 3–30 of life -1 group received placebo	<32 w	The Netherlands	PCV 7 (4 doses at 2, 3, 4 and 11 months of age)	to investigate the specific antibody levels against the 7 pneumococcal vaccine serotypes 4– 6 weeks after the third pneumococcal immunization and 4– 8 weeks after the booster dose	- IgG antibody levels in preterm infants supplemented with oligosaccharides were similar to those of term infants at 5 months of age, while IgG antibody levels in preterm infants supplemented with placebo were higher for 5 of the 7 vaccine serotypes (serotypes 4, 6B, 9V, 19F, 23F; $P < 0.05$) than those in term infants. -At 12 months of age, there was a significant booster response in both preterm groups and the GMCs of pneumococcal antibody levels after the booster dose for all serotypes were not different in the two groups -preterm infants with higher gestational age showed higher pneumococcal antibody concentrations of certain		
Szynczewska et al (2014) 65	Observational prospective	60 -Group I 23 born with birth weight <1000 g; -Group II 37 born with birth weight ≥1000 g	24-34 weeks	Polonia	PCV7	To assess concentration of specific immunoglobulin G against all seven serotypes of PCV7 4 weeks after the primary vaccination; prior and 4 weeks later the booster dose administration.	serotypes at 5 and 12 months - After primary immunization, an increase in the average concentration of antibodies for all serotypes was observed in most children, with no significant differences between groups. -Serotypes 6B and 23F proved to be the least immunogenic following the primary vaccination -Prior to administration of the booster dose at age 16 months a significant decrease in antibody titer was observed in all children - The last vaccination resulted in another significant increase in the concentration of antibodies in both groups.		
Ichikawa et al (2013) 41	Observational prospective Clinical trial	161 (17 received early vaccination at 6 months)	< 34 w	Japan	Measles	To evaluate antibody titers before and after early vaccination at 6 months for measles	-The antibody titers at birth was significantly lower in preterm infants born <28 weeks ($P < 0.05$) and with a weight <1000 g ($P < 0.01$). -At 3–6 months of age, none of the 108 infants tested had protective antibody titers. -Preterm infants who received early vaccination at 6 months kept antibodiy titers positive in all cases 1 month after vaccination. -Titers did not decay during the 12 months after vaccination	Small size	sample
Vermeulen et al. (2013) 70	Observational prospective cohort study	68 -22 vaccinated with whole cell pertussis vaccine (Pw) -24 vaccinated with two components	<31 w	Belgium	3 type of vaccines: Pw, Pa bicomponent, Pa multicomponent	To assess at one year of age the specific cellular immune responses in the preterm infants (through cytokine	-more than half of premature infants vaccinated with the Pw vaccine or with the 2 component Pa vaccine developed at 3 and/or at 6 months of age an IFN-s response to FHA and/or PT	Small size	sample

	acellular vaccine (Pa) -22 vaccinated with three component Pa vaccine.				secretion after antigenic stimulation)	 no effect of the booster dose was observed on the FHA or PT- induced IFN- γ secretion in the 3 groups Pa vaccine induced more secretion of Th2 cytokines in response to FHA and to PT, compared to infants primed with a Pw vaccine 	
Omenaca et al. (2012) 46	,	\geq 27 and <37 w	France, Portugal, Poland, Spain	Rotavirus	To assess immunogenicity of a human rotavirus vaccine dosing IgA specific antibody concentrations 30–83 days post-dose 2	seroconversion rate at 30–83 days post dose 2 of vaccine/placebo was 85.7% (95% CI: 79.0– 90.9%) in vaccine group and 16.0% (95% CI: 8.8–25.9%) in the placebo group	
Tsuda et al. Observationa (2012) 47 prospective cohort		<37 w	Japan	Hib	to evaluate vaccine immunogenicity in preterm infants by measuring antibody PRP titers as GMCs before and 1 month after the third dose	- after three doses of vaccine, GMCs increased from 0.06. to 2.89 mg/mL ($P < 0.001$). -The seroconversion rate was 85.2% - the seroconversion rate after vaccination of infants with a history of antenatal exposure to steroids was higher than those without antenatal exposure ($P = 0.046$). - the seroconversion rate of group vaccinated at the age of 2 months was close to being significantly worse than the group vaccinated at the age of >3 months ($P = 0.060$)	Small sample size
Esposito et Prospective, al. (2011) 48 randomized study	101	-34 born <32w -35 born 32-36 w -32 born ≥37w	Italy	Influenza A/H1N1 MF59- adjuvanted vaccine	To assess immunogenicity of influenza A/H1N1 ^{MF39} -adjuvanted vaccine in preterm and term children aged 6 to 23 months evaluating antibody titers collected immediately before administration of dose 1, dose 2 and 4 weeks later the dose 2.	-the first dose was able to determine seroprotection in all of the preterm born between 32 and 36 weeks of gestation -After the administration of the vaccine, there was a significant increase in the GMCs of all the children (P <0.05) -The preterm subjects with a gestational age <32 weeks aged 6 to 11 months had significantly lower absolute GMCs than the subjects in any of the other groups (P<0.05)	
Omeñaca et al. (2011) 54 clinical trail		-preterm group I (between 27 and 30 w); -preterm group II (between 31 and 36 w -term group	Spain, Greece	PHiD-CV	To evaluate immunogenicity to PHiD-CV at 2, 4, and 6 months of age evaluating antibody titers like OPA o GMC 1 month after primary vaccination, and 1 month after booster vaccination.	-at least 92.7% of infants in each group had antibody GMCs concentrations>0.2µg/mL and at least 93.2% of subjects had OPA titers >8 1 month after primary immunization. -preterm infants showed lower antibody titers for certain serotypes -at least 97.6% of subjects in each group developed antibody concentrations >0.2 µg/mL 1 month after boster dose. -One month after both primary and booster vaccination, all subjects were seroprotected/seropositive for antibodies against the antigens of the coadministered vaccines, except 1 subject in preterm group I after primary vaccination who was not seroprotected against polio type 3.	
Omenaca et phase III al, (2011) 53 open, controlled multicenter prospective study	b 309	-56 preterm I: ≤31 w - 107 preterm II between 32 and 36 w -150 full term infants	Spain	Hib-MenC-TT and PCV7 at 2, 4, 6 months and at 16 to 18 months of age	to evaluate the immunogenicity of Hib-MenC-TT in formerly preterm infants measuring antibody specific titers 1 month postdose 3 and 1 month after the booster dose.	 the percentage of subjects with seroprotective anti-PRP antibody concentrations was ≥99% in all groups. Booster vaccination induced marked increases in anti-PRP antibody GMCs, after a reduction of the percentage of subjects with seroprotective anti PRP before the booster At least 99.0% and 97,3% of 	Open design

	-		-			-		
							subjects in each age stratum had	
							rSBAMenC titers $\geq 1:8$ postprimary vaccination and post	
							booster dose respectively.	
							- At least 97.5% of infants in	
							each age stratum had anti-HBs	
							concentrations >10 mIU/mL at 1	
							month postdose 3 -The postdose 3 anti-HBV GMCs	
							was significantly lower in the	
							preterm I group than in the	
							preterm II and full-term groups	
Baxter et al	Prospective	131	<32 w	UK	DT-Hib-MenC-	to show antibody	-98.3% and 100% of premature	
(2010) 72	pragmatic case series				PCV	response in premature infants to DT-Hib-	infants respectively developed a minimum protective antibody	
	cuse series					MenC-PCV, in a	response;	
						routine clinical	-86.6% premature infants were	
						situation	protected against Men C.	
							However, only 67.8% preterm	
							infants achieved anti-polyribosyl	
							ribitolphosphate (PRP) antibodies	
							>0.15µg against Hib	
							-Responses to the different pneumococcal serogroups ranged	
							from 67.5% to 92.5%.	
							- In comparison to term infants,	
							preterm infants were less likely to	
							achieve protective levels against	
							MenC and Hib -Protection was inferior to	
							expected based on published	
							premature infant clinical trial data	
							for Hib, some pneumococcal	
			-22.27	110.4		T 1	serotypes and Men C.	
Klein et al. (2010) 50	Observational open-label	88 -33 ≤33 w	≤33-37 w	USA	IPV	To compare the humoral and cellular	-preterm and term infants developed comparable mean	
(2010) 50	prospective	-50 >37 w				immune responses of	frequencies of poliovirus-specific	
	study					preterm infants to	memory T cell responses	
						those of term infants	- About mononuclear cells	
						after the primary	(PBMCs) proliferation preterm	
						series of IPV given as part of a combination	infants were significantly less likely to have a positive	
						vaccine	stimulation index (SI) than term	
							infants (P=0.03)	
							- All infants with serum available	
							for testing had a seroprotective	
							antibody response to all 3 poliovirus serotypes	
			XX				-The GMCs to poliovirus serotype	
							1 was significantly lower in both	
							the group of all preterm infants	
Moss et al.	Observational	184	-132 preterm	UK	PCV7	To assess	- only 36% term infants and 34%	
(2010)	prospective		infants -52 full term		administered with Neisseria	pneumococcal serotype-specific IgG	preterm infants achieved putatively protective levels	
			infants		meningitidis	antibody	against all 7 vaccine serotypes,	
					group C (MCC),	concentrations for all	- At 12 months of age, only 22%	
					diphtheria,	PCV7 4 weeks	term infants and 11% preterm	
					tetanus,	following the third immunization, and	infants had putatively protective	
					pertussis, polio, and Hib	immunization, and either at 12 months of	levels against all vaccine serotypes	
					vaccines	age or 4 weeks after a	- There was a significant increase	
						booster dose of PCV7	in GMCs for both term and	
							preterm infants for all serotypes,	
							including the 2 control serotypes from post-primary immunizations	
							to post-fourth dose ($P < 0.01$)	
							- Preterm birth adversely affected	
							the GMCs to serotypes	
0	0	192	02	Que :	DTD- UNV	T	4, 6B, 14, 19F, and 23F (P <0.01).	
Omeñaca et al. (2010) 73	Open label trial	182 -93 preterm infants	-93 preterm infants	Spain	DTPa, IPV, HBV, Hib	To assess Hepatitis B response of	-A total 93.4% preterm and 95.2% full-term infants responded to	
ai. (2010) /3		-89 full term infants	-89 full term		110 , 110	premature infants	primary vaccination	
			infants			after primary and	-Six preterm infants (6.59%) did	
						booster immunisation	not respond to primary	
						with hexavalent	immunization and failed to	
						vaccine	respond to the booster dose -No responders had a gestational	
							age of at least 31 weeks and,	
							except for two, were severe IUGR	
Faridi et al.	Observational	143	31-41 w	India	BCG	To evaluate	-95.8% had either a reactive	
(2009) 63	prospective	1	1			immunogenicity of	Mantoux test or positive LMIT 6	

study			BCG in	preterm	months after BCG vaccination.	
			infants	through	-There were only 6 babies (4.2%)	
			Mantoux	test	who did not show adequate	
			conversion	at 12	responses to BCG vaccination.	
			weeks and	6 months		
			of age ir	babies		
			vaccinated v	with BCG		
			at birth			

Table 4. Studies regarding vaccine immunogenicity in preterm infants [Notes:

DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H. influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test].

Study	Design	No of pts	Gestational	Location	Vaccination	Objectives	Results	Bias
(year)		201	Age	F	D. (
Roué et al. (2014) 45	Observational prospective population- based study	201	<37 w	France	Rotavirus vaccine	To evaluate the impact of the pentavalent rotavirus vaccine on the number of hospitalizations for rotavirus diarrhoea in preterm infants enrolled in the IVANHOE study.	- After introduction of the vaccination program, a 2.6- fold (95% CI, 1.3 to 5.2) and an 11-fold (95% CI, 3.5 to 34.8) decrease in the number of hospitalizations for rotavirus was detected in two epidemic seasons in prematurely born infants younger than 3 years of age	
Shen et al.	Observational	683,354 (52903	Preterm and	Canada	Influenza	to estimate the	-Full vaccination was associated	
(2013) 69	retrospective	preterm infants)	full-term infants	· SO		effectiveness of seasonal influenza vaccination in all pre- and full-term infants aged 6–23 months examining influenza-coded ambulatory visits (physician office and ED visits) during influenza season periods.	with an overall 19% reduction in ambulatory visits (HR = 0.81 ; 95% CI, $0.68-0.97$) -Among preterm children, full vaccination was associated with a non-significant, 28% reduction (HR = 0.72 ; 95% CI, $0.40-1.29$). -Partial vaccination appeared ineffective in all groups.	
Rückinger et al (2010) 68	active prospective surveillance trial	766,999 in 2000 684,862 in 2007	number of preterm born children was estimated based on the assumption that about 7% of children in Germany are born preterm.	Germany	PCV7	To evaluate the impact of PCV7 on IPD in preterm born infants comparing children born in 2000 (the only birth cohort of unvaccinated children) with those born in 2007	 A reduction in notifications of IPD per 100,000 from 15.0 to 8.5 (P < 0.001) in 2007 was found. A reduction in notification rate from 26.1 to 16.7 per 100,000 comparing the 2000 with the 2007 was found also in preterm birth cohort but it was not significant (P = 0.39) No preterm infants with reported IPD had received full vaccination with booster dose according to the recommended scheme. In two cases a serotype included in PCV7 was found. These two cases had not received pneumococccal vaccination prior to disease onset, although they were at an appropriate age. 	- exact number of preterm born infants in Germany is unknown

Hviid	Observational	879,424	≥20	Denmark	Pw and	Pa	Effectiveness of two	-For whole-cell vaccinated	
(2009) 71	retrospective	-preterm infants			vaccine		pertussis vaccines in	children, the difference in	
() .	nationwide	59,311					preterm Danish	effectiveness estimated between	
	cohort study	-full term infants					children through	preterm and full-term children	
		820,113					evaluation of	was statistically significant (p =	
							pertussis	0.0134).	
							hospitalisation	-We found that preterm children	
								were at 91% increased risk (95%	
								CI, 21-200%) compared to full-	
								term children after one dose of	
								whole-cell vaccine.	

Table 5 Studies regarding vaccine effectiveness in preterm infants. [Notes: DTaP=diphtheria, tetanus, acellular pertussis vaccine; IPV= inactivated polio vaccine; OPV=oral polio vaccine; HBV=hepatitis B vaccine; PCV7 heptavalent antipneumococcal vaccine; PCV13= tridecavalent antipneumococcal vaccine; Hib= type B Haemophilus influenzae vaccine; Hib-MenC-TT= Haemophilus influenza type B-Neisseria meningitidis serogroup C vaccine; BCG= Bacille Calmette-Guérin vaccine; PHID-CV =PCV10-non typeable H. influenzae protein D conjugate vaccine; SNAP-II: Score for Neonatal Acute Physiology II (SNAP-II), MMR=measles, mumps, and rubella vaccine; GMCs= geometric mean concentrations; PRP= anti-polyribosylribitolphosphate; IPD= invasive pneumococcal disease; LMIT=leukocyte migration inhibition test, IC=interval confidence; ED=emergency department; HR= Adjusted hazard ratios; Pw=pertussis whole vaccine; Pa=pertussis acellular vaccine].




Figure 1: Four-phase flow diagram of the systematic review in accordance with PRISMA guidelines[40].

Figure 1

Four-phase flow diagram of the systematic review in accordance with PRISMA guidelines[40].